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CHAPTER 1: INTRODUCTION 
1.1 Introduction 
 Despite numerous advances in science and technology, the field of vaccine 
design has changed relatively little in the past century1. Current vaccine technology 
relies on a simple and often inefficient formula of killing a pathogen, removing its ability 
to replicate in a host, or selecting out virulence factors before delivery. This method can 
be slow, costly, and relies mostly on a process of trial-and-error1–3. Most importantly, 
this approach rarely provides cross-protection against clades, serotypes, or strains of 
highly variable pathogens, such as influenza, which require a seasonal immunization 
based on circulating strains1,4. Current seasonal influenza vaccines are manufactured 
using traditional methods of live-inactivated (“nasal-spray flu vaccine”) or killed vaccines 
(“flu shot”)5,6. Live vaccines consist of attenuated organisms lacking in pathogenicity 
due to the removal of their virulent properties7. Live vaccines are very potent due to the 
pathogens’ effector mechanisms remaining intact and can pose considerable safety 
risks such as the reversion of the pathogen back to its virulent state. Inactivated or killed 
vaccines contain virulent organisms that have been rendered incapable of replication. 
Inactivated vaccines are safer than live vaccines but are generally less immunogenic 
and poor inducers of cellular immunity7.  
 Next-generation vaccines have the potential to be safer, easier to produce, and 
to induce cross-protection against a given pathogen. In recent years, subunit vaccines 
have grown in popularity. This type of vaccine contains only a part of the infectious 
microorganism and offers multiple advantages over a traditional live or attenuated 
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vaccine. Subunit vaccines can efficiently induce an efficient antibody response and 
cellular immunity without the safety constraints of live vaccines8. This is because 
subunit vaccines have no risk of pathogenicity since the microorganism itself is 
completely absent 9. Subunit vaccines can also be manufactured in a scalable cost-
effective manner. These vaccine types have already been proven effective against 
various diseases in animal models8. The antigen subunits such as protein or DNA 
however, are typically not strong enough to elicit an immune response to protect against 
an infection. A vaccine additive called an adjuvant is needed to significantly boost the 
immune response against the antigen3. The addition of an adjuvant to vaccines can 
improve the immune response in many different ways: they can enhance the 
immunogenicity of antigens; they can modulate an appropriate immune response; or 
they can decrease the dose of the antigen required and the number of immunizations 
necessary to establish long-lasting immunity10. The proposed mechanisms of 
adjuvanticity vary and include inflammation, increasing cellular uptake, promoting the 
activation of antigen presenting cells, or inducing cytokines11.  
 Although many substances have been tested as adjuvants, very few have been 
proven useful, and fewer have been approved for commercial use. The primary obstacle 
that researchers developing adjuvants must overcome is toxicity1,11. By far the most 
commonly used adjuvant in the United States is an aluminum-based adjuvant 
formulation consisting of aluminum hydroxide and aluminum phosphate known as 
alum12. Although alum has been deemed safe, its multiple disadvantages necessitate 
the search for new adjuvants. High levels of alum can increase the functionality of the 
adjuvant but proportionally raise the level of cytotoxicity making alum unsuitable for low 
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immunogenicity subunit vaccines. Alum vaccines cannot augment a cell-mediated 
response or be administered orally or intra-nasally and have occasionally been 
associated with allergic and tissue reactions7. In 2009, the FDA approved the use of 
one additional adjuvant, AS04, a combination of aluminum hydroxide and 
monophosphoryl lipid A for use in a vaccine to prevent cervical cancer caused by 
human papillomavirus types 16 and 1813.  
 Next -generation polymeric adjuvants offer several advantages over conventional 
adjuvants. Polymer-based vaccines have demonstrated the potential to induce both 
humoral and cell-mediated immune responses when administered alongside an 
antigen14. By tailoring polymer degradation kinetics, antigen can be slowly released over 
long periods of time14. Additionally, the precursors of synthetic polymeric adjuvants are 
unlikely to contain reactive or allergenic epitopes7. Polymeric adjuvants can also be 
further tailored to incorporate immunomodulatory properties.  
 Cationic pentablock copolymers designed and synthesized in our laboratory have 
several characteristics that make them strong candidates for a DNA vaccine adjuvant. 
The central triblock of the pentablock copolymers is composed of Pluronic F127, an 
FDA approved nonionic block copolymer15. Pluronic has a central hydrophobic chain of 
polyoxypropylene and two hydrophilic chains of polyoxyethylene. The hydrophobic 
interactions between collapsed polyoxypropylene blocks result in the formation of 
micelles. Hydrophobic portions of particles are identified by the body as foreign, and 
enhance cell adhesion and phagocytosis by macrophages16,17. Pluronic also promotes 
cellular endocytosis and high gene expression18–20. The outerblocks of the pentablock 
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copolymers that are added during the atom transfer radical polymerization (ATRP) 
reaction offer several critical advantages. The amine groups on the pentablock 
copolymer outerblocks form a complex with DNA spontaneously as a result of 
electrostatic interaction21. Studies with one of these pentablock copolymers have shown 
that the polymer micelles aggregate to form physical gels at high polymer 
concentrations, to offer sustained gene delivery and provide a platform for the 
combinational therapy of gene and drug co-delivery22–24. The bromine end groups can 
be modified to attach fluorochromes for intracellular tracking or sugars such as 
mannose that are ligands for pattern recognition receptors on antigen presenting cells25–
27
.  
 The main objective of this project is the development of a safe and effective 
vaccine against the highly pathogenic avian influenza (HPAI) H5N1. Influenza A viruses, 
such as  HPAI H5N1, constantly circulate in animal hosts and when crossed into human 
populations have caused devastating pandemics resulting in millions of fatalities28. 
These viruses are subtyped according to the antigenic properties of the surface proteins 
hemagglutinin (HA) and neuraminidase (NA). The nomenclature of the Influenza A virus 
subtypes comes from the characterization of these two surface proteins28. Since its 
isolation from geese in 1996, the HPAI virus subtype H5N1 avian influenza has been 
one of the most highly publicized emerging influenza strains. Infection with H5N1 has a 
60% case-fatality rate and has been shown to be virulent in traditionally resistant animal 
populations such as water fowl and cats29,30. As recently, and controversially, published 
in Science, a change in as few as five amino acids in HPAI H5N1 leads to the potential 
for the virus to transverse human hosts directly31. According to the U.S. Food and Drug 
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Administration (FDA) HPAI H5N1 is a potential candidate for the next pandemic32. 
Therefore there is an urgent need to create an efficacious vaccine for prevention and 
control of HPAI H5N1.  
 In order to design an efficacious next-generation vaccine against HPAI H5N1 
several specific research goals were laid out including: (1) Design, synthesis, and 
optimization of the pentablock copolymer vaccine platform; (2) Evaluation of vaccine 
efficacy in vitro and in vivo; and (3) Immunization of mice with the pentablock copolymer 
vaccine to asses an immune response. The ultimate aim of the pentablock copolymer 
platform is the application the HPAI H5N1.The final dissertation is organized into eight 
chapters.  
 Chapter 2 is a review article published by Technology in February of 2014 that 
summarizes the current status of polymeric adjuvants with an emphasis on tailorability 
through polymer modification and functionalization. This review article encompasses a 
wide range of both synthetic and natural polymeric adjuvant formulations.  
 Chapter 3 is a paper published in Macromolecular Chemistry and Physics in May 
of 2013 that demonstrates a novel atom transfer radical polymerization (ATRP) catalyst. 
The controlled architecture of the pentablock copolymers is possible by means of 
ATRP. The application of easily removable cuprous oxide nanparticles has yielded 
pentablock copolymers with no residual copper in in the final product. Pentablock 
copolymer synthesized with cuprous oxide nanoparticles have several advantages over 
those catalyzed by traditional inorganic salts. Most significantly, these block copolymer 
6 
 
have a measurable decrease in cytotoxicity in vitro with a presumable increase in 
biocompatibility in vivo.  
 Chapter 4 is a paper published in RSC Advances in March of 2014 that features 
the synthesis of several pentablock copolymers with different cationic blocks and their 
functionalization with pathogen-associated mannose to create virus-mimicking 
nanoparticles. All four of the pentablock copolymers were evaluated for their ability to 
condense DNA and their ability to safely transfect cells. The pentablock copolymers 
were functionalized with a pathogen-associated carbohydrate, a ligand for pathogen 
recognition receptors on antigen presenting cells. The attachment was confirmed and 
quantified through multiple methods including zeta potential measurements and a 
phenol sulfuric acid assay. From these, suitable vaccine candidates were identified.  
 Chapter 5 is a paper submitted to Acta Biomaterialia that investigates the ability 
of these pentablock copolymers to deliver structurally intact and antigenically stable 
protein. We also evaluated the sustained release of model protein antigen in vitro and 
the ability of the block copolymer system to form in vivo depots. These results 
demonstrate the potential of these block copolymers hydrogels to persist for several 
weeks and sustain the release of antigen with minimal effects on protein stability and 
antigenicity; and their ability to be used simultaneously as a sustained delivery device 
as well as a protein-based subunit vaccine adjuvant platform. 
 Chapter 6 is a comprehensive safety study of the block copolymer system. We 
investigate the biocompatibility of our platform with a ProSense 750 inflammation study, 
histopathological analysis as well as serum and urine biomarker analysis. In response 
7 
 
to discovering hyperlipidemia in mice administered Pluronic F127, we made additional 
modifications to the hydrogel formulation. We then demonstrate the safety of this 
optimized formulation as well as its capacity to instigate quantitative immune responses. 
 Chapter 7 includes a low pathogenic influenza H5N1 challenge study in 
collaboration with the University of Nebraska Medical Center in Omaha, Nebraska. This 
work includes the evaluation of neutralizing antibody titers, weight loss, viral load and 
BAL cytokines. With it, we demonstrate the efficacy of the optimized pentablock 
copolymer vaccine platform. 
 Finally Chapter 8 includes a conclusion on the establishment of the optimized 
pentablock copolymer system and includes future directions for the vaccine platform.   
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2.1 Introduction 
 Despite many advances in medicine and technology, infectious diseases remain 
a significant global threat1,2. In recent years, there have been countless studies 
published on the mechanisms of the immune response to infections and how this can 
affect pathogenesis. Yet, the field of commercial vaccine development has remained 
largely unchanged for decades, relying primarily on aluminum salts (i.e. alum) to 
enhance the immunogenicity of antigens3–5. The human immune system is a complex 
network of immune molecules and signaling pathways that responds to individual 
pathogens in a unique manner6–9. Therefore, the practice of using an off-the-shelf 
vaccine adjuvant is no longer an optimal approach to vaccine design. Given the 
numerous advances made in immunology, chemistry and polymer design, a rational 
approach to vaccine design based on favorable interactions between the immune 
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system and novel polymeric vaccine adjuvants offers the opportunity for improved 
efficacy over traditional vaccines10.  
 An ideal vaccine adjuvant must bridge the gap between innate and adaptive 
immunity, to not only initially engage the immune system, but also elicit a successful 
memory response against future infections11,12. Immune cells such as macrophages and 
dendritic cells recognize invading pathogens through pattern recognition receptors 
(PRRs) which recognize pathogen-associated molecular patterns (PAMPs) on viruses, 
bacteria, and other pathogens13. Not surprisingly, different pathogens present different 
molecular signals, which, in turn, activate different immune system responses14. Recent 
data also suggests that the central mechanism of adjuvanticity that was once attributed 
to antigen adsorption, a process known as the depot effect, may instead be through the 
engagement of PRRs5,15,16. Given the increased knowledge of how pathogens and 
adjuvants interact with the immune system, it is now possible to design novel vaccines 
to better train the immune system to respond to specific pathogens. 
 In addition to alum, MF59 and AS03, two squalene-based oil-in-water emulsions, 
and AS04, an amalgam of monophosphoryl lipid A (MPLA) and alum, have recently 
been adopted into licensed vaccines15. Many other potential adjuvants have been 
reported in the scientific literature including saponin containing immune stimulatory 
complexes (ISCOMs), microbially-derived, cytokines including granulocyte-macrophage 
colony stimulating factor (GM-CSF) and liposomes comprised of cholesterol and 
phospholipids17–19.  
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 Polymers have also been studied for many years as adjuvants as they offer a 
unique set of advantages over more conventional adjuvants. One such advantage is 
that the size, molecular weight and chemistry of polymers can be tailored to target 
various cells of the immune system20. Polymers that have been extensively evaluated 
as vaccine adjuvants include polysaccharides, polyesters and non-ionic block 
copolymers. These polymers can be further modified with other components including 
carbohydrates to activate PRRs that may provide an optimal immune response against 
a given pathogen3. 
2.2 Immune Responses 
 The host response against invading pathogens is a function of the immune 
system which has evolved into two interrelated branches: an innate system that 
responds rapidly (within minutes) in a non-specific manner to highly conserved regions 
on pathogens as a first line of defense; and an adaptive system that responds relatively 
slower (days to weeks) using randomly generated highly specific receptors with a 
seemingly limitless specificity that establishes immunological memory. Together the 
innate and adaptive branches form a highly efficacious immune system that identifies 
and neutralizes invading microorganisms14,21.  
2.2.1 Innate Immunity 
 Innate immunity provides an immediate defense against infection through a 
network of physical and chemical barriers, antimicrobial agents, cellular defenses and a 
complement system that assists phagocytic cells and antibodies in clearing pathogens. 
This is all accomplished by effectively identifying pathogen invaders. The difficulty in 
14 
 
recognizing pathogens is their extreme variability and high mutational rate. To alleviate 
this, the potential targets for the innate immune system are recurring molecular 
structures that are present in a large group of pathogens. The targeted molecular 
patterns are conserved regions where genetic changes are selected against because 
they are essential for the pathogenicity or survival of the pathogen. These targeted 
molecular structures are called pathogen-associated molecular patterns (PAMPs) and 
are recognized by pattern recognition receptors (PRRs) on host immune cells13,22,23. 
 The innate immune system relies on PRRs to detect invading pathogens that are 
expressed in many cell types including immune cells. These PRRs consist of membrane 
associated toll-like receptors (TLRs), C-type lectin receptors (CLRs), cytoplasmic NOD-
like receptors (NLRs) and RIG-I like receptors (RLRs)24. The first identified class of 
PRRs are TLRs which consist of ectodomains containing leucine-rich repeats that 
recognize pathogens, and an intracellular Toll/IL-1 receptor (TIR) domain that is 
required for downstream signal transduction25,26. TLRs detect invading pathogens 
outside of the cell as well as inside endosomes and lysosomes by recognizing a variety 
of PAMPs27. NLRs and RLRs are cytosolic PRRs that are primarily involved in bacterial 
and virus recognition respectively28. Many members of the CLR family bind 
carbohydrates that often make up of PAMPs and may consequently induct signal 
cascades that elicit microbicidal or inflammatory responses29.  
 The recognition of PRRs by PAMPs regulate the expression of co-stimulatory 
molecules on APCs and induce effector cytokines that instruct the type of adaptive 
immune response22. The signals induced by the ligation of PRRs can regulate an 
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adaptive immune response in multiple ways. Inflammatory cytokines such as Type 1 
interferon (IFNs) induced by viruses can up regulate the expression of MHC class 1 
molecules thereby improving the presentation of peptides to cytotoxic T cells.  Other 
signaling molecules including IL-1, TNF-alpha and chemokines direct the migration of 
antigen specific lymphocytes into the site of infection by activating adhesion molecules. 
Finally, the induced signals can control effector functions such as IL-6 that induces the 
differentiation of B-lymphocytes into plasma cells22. 
2.2.2 Adaptive Immunity 
 The major functions of the adaptive immune response are to recognize specific 
non self-antigens, generate a tailored response to eliminate the threat and develop an 
immunological memory22. A tailored response is possible through the cell-mediated and 
humoral components of adaptive immunity that respond to the presentation of antigen 
on MHC class I & 2 molecules respectively. The cell-mediated arm primarily involves 
cytotoxic T-lymphocytes that kill cells already infected with invading pathogens. 
Humoral immunity protects the extracellular space by means of B-cell produced 
antibodies that opsonize and clear pathogens30. The generation of memory B-
lymphocytes and T-lymphocytes provide immunological memory that protects against 
reinfection. Given the complexity of the innate and adaptive immune responses and the 
interplay between the two, it is easy to conclude that the type of adaptive responsive 
that works best against one pathogen may not work for another. Protection against most 
viral and bacterial infections is mediated by humoral immunity, but for intracellular 
infections such as Mycobacterium tuberculosis and Leishmania major, a cell-mediated 
response is required. Protection against other diseases including Human 
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immunodeficiency virus (HIV) infection and herpes is likely to require both31. This 
supports the need to target a vaccine adjuvant specifically to the pathogen to elicit the 
most effective immune response. 
2.3 Vaccine Types 
 Vaccines may be classified into three categories: live, inactivated and subunit 
vaccines. Live vaccines consist of attenuated microorganisms that replicate similar to 
the natural microorganisms, but without their virulent properties. These vaccines can 
elicit an immune response similar to a natural infection, since the microorganism retains 
its ability to replicate in the host32. In addition to the ability of live vaccines to mimic a 
natural infection, the integrity of the pathogen-associated molecular patterns retain their 
ability to stimulate an innate immune response33. These vaccines induce potent immune 
responses, generally confer long lasting protection, require no adjuvants and fewer 
innoculations34. There are multiple methods of accomplishing attenuation of the 
microrganisms’ pathogenicity.  The wild-type pathogen can be passaged in a nonhuman 
host or in vitro, and artificially selected, such as the oral polio vaccine32. Mutants can be 
selected in vitro that grow below physiological temperatures and replicate less 
frequently than wild-type pathogens in vivo; as for example, a widely tested cold-
adapted influenza vaccine32. Viruses from other species can be selected that can elicit 
protective immunity to human pathogens without disease; a good example is the 
smallpox 32. Smallpox was eradicated using a variant form of the vaccina virus isolated 
from cows35. The attenuated microorganisms are manufactured in bacterial culture 
media or supernatants of cells33. In addition to the complex and time consuming trial-
and-error method of development, live vaccines pose several challenges to safety. An 
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attenuated microorganism may persist and induce disease in immunocompromised 
recipients34. Another concern is that modified microorganisms can revert to a virulent 
state through random mutations and horizontal gene transfer34.  
 A method of safely administering a microorganism for a vaccine is to kill or 
inactivate it, rendering it incapable of replication. Killed vaccines are prepared similar to 
live vaccines except the purified microorganisms are inactivated with heat or treatment 
with chemicals such as formaldehyde and -propiolactone33,34.  In addition to fewer 
safety risks than live vaccines, killed vaccines are generally cheaper to produce and 
have a longer shelf life34. Killed vaccines are also less immunogenic than live vaccines 
due to the inability of the microorganism to replicate in the host, and therefore are often 
administered with an adjuvant33. They do not effectively elicit a cell-mediated immune 
response due to the microorganisms’ inability to deliver antigen to endonogenous MHC 
I33. Nevertheless the preserved epitopes are potent inducers of humoral immunity, 
making killed vaccines a popular choice for antibody-mediated protection33,34. Killed 
vaccines often require multiple doses and can have adverse side effects such as the 
high fever caused by the inactivated whooping cough vaccine34. Examples of killed 
vaccines include immunizations against hepatitis A, influenza, whooping cough and 
typhoid fever33.  
 When a specific antigen is identified to elicit protective immunity, it can be 
isolated and administered directly in the form of a subunit vaccine. Subunit vaccines 
contain protective epitopes of a pathogen such as a protein or DNA encoding thereof.  
The absence of microbial components that do not induce protective immunity but cause 
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adverse reactions such as strong inflammatory inducing TLR ligands, make subunit 
vaccines a safer alternative to live or killed vaccines34. Protein-based vaccines currently 
in use include inactivated toxoids derived from diphtheria and tetanus toxoids as well as 
Haemophilus influenzae B polysaccharides conjugated to carriers33. The only currently 
licensed vaccines that induce cellular immunity efficiently are live vaccines, but they are 
limited by safety concerns and manufacturing concerns31.  The expressed epitopes 
encoded by DNA-based vaccines are presented on endogenous MHC I and can also 
elicit a cell-mediated immune response34. DNA vaccines have been proven effective 
against various diseases in animal models but human vaccines are still in clinical 
trials31. The primary limitation of subunit vaccines is that antigen alone induces little or 
no immune response and requires the use of an adjuvant for boosted immunogenicity34. 
The use of subunit vaccines has intensified the search for more potent adjuvants11.  
2.4 The Ideal Adjuvant 
 Many protective antigens have poor immunogenicity and are incapable of 
eliciting an immune response strong enough to establish memory cells for protective 
immunity. Any substance incorporated into a vaccine to enhance an immune response 
is designated as an adjuvant. Additional core functions of adjuvants may include 
providing a depot effect for sustained release of antigen and immune modulation. With 
the increasing use of synthetic and recombinant vaccines with poor immunogenicity, the 
need for potent adjuvants is more important than ever19. Relevant properties of an 
adjuvant to consider include shelf life, available administration routes, biocompatibility 
and the promotion of a cell-mediated or humoral immune response19. All of these 
qualities must balance toxicity from local and systemic reactions and the induction of 
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autoimmune disease. Adjuvant selection is dependent on the pathogen, species, route 
of administration and the antigen19. There is no single adjuvant that can be 
recommended for all universal vaccines36. 
2.5 Conventional Adjuvants 
2.5.1 Mineral Salts 
 Aluminum salts, referred to as ‘alum’, are the most widespread adjuvants in 
human and veterinary vaccines4. Aluminum adjuvants adsorb antigen, and thus the 
optimal formulation is dependent on electrostatic forces and the physiochemical 
properties of the antigen37. The most commonly used aluminum adjuvant formulations 
consist of aluminum hydroxide and aluminum phosphate. The mechanism of 
adjuvanticity of alum, like most adjuvants, is not completely understood, but several 
mechanisms are cited frequently. The formation of a depot by alum after administration 
allows a continuous release of antigen38. Antigen adsorbed by alum has an increased 
chance of being phagocytosed by APC as opposed to soluble antigen due to its 
particulate nature4,39. Other possible mechanisms include the activation of the 
complement system and the stimulation of macrophages38. Alum adjuvants can 
primarily be found in human vaccines against hepatitis A, hepatitis B, diphtheria, 
pertussis, poliomyelitis and tetanus39. The advantages of aluminum adjuvants include 
antigen stabilization, a proven track record of safety and augmented humoral immune 
response4. Limitations include allerginicity, ineffectiveness for some antigens, inability to 
be frozen and increased IgE production37,40. Alum is a poor inducer of cytotoxic T-
lymphocyte responses4. Even with current limitations, aluminum adjuvants will continue 
to be used as a gold standard for other adjuvants formulations due to its strong 
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presence in human vaccines. Other mineral salts that have been used to adsorb 
adjuvants include calcium, iron and zirconium salts40. Calcium phosphate was 
effectively used in several human vaccines including diphtheria and tetanus before its 
replacement by alum in the 1960s41. 
2.5.2 Emulsions 
 In the 1930s, Dr. Freund discovered that immunizations of protein antigen with 
killed Mycobacterium tuberculosis produced relatively high antibody titers in a water-in 
mineral oil emulsion42. This led to the development of Complete Freund’s Adjuvant 
(CFA) and, in instances where the mycobacteria was not required, Incomplete Freund’s 
Adjuvant (IFA)42. Mechanisms of adjuvanticity of both CFA and IFA emulsions include 
the formation of a depot at the site of injection that allows a gradual release of antigen 
over time and altered trafficking to critical sites40. These adjuvants have been shown to 
induce strong antibody responses with protective immunity but success in human trials 
has been hindered by swelling, granuloma formations and localized abscesses42. Today 
Freund’s Incomplete Adjuvant is most commonly used in veterinarian vaccines where 
aluminum adjuvants have failed42. Freund’s Complete Adjuvant is generally regarded as 
too toxic for humans and instead used to induce autoimmune disease in experimental 
animal models. The high reactogenicity of these adjuvants have led to an evaluation of 
other purification methods, emulsifiers and sources of oils. Variations of water-in oil 
emulsions include Montamide ISA 51 and ISA-72043. MF59 is a licensed oil-in-water 
emulsion that is available in several countries44.  
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2.5.3 Immune Stimulatory Complexes (ISCOMs) 
The first generation of Immune Stimulatory Complexes (ISCOMs) were 
developed in Sweden by Dr. Bror Morein in the 1980s. ICOMs are spherical open cage-
like structures around 40 nm in diameter containing complexes of cholesterol, 
phospholipids and saponins. The key component, the saponin, which is extracted from 
the bark of the Quillaia saponaria tree, has long been known to promote an immune 
response.  ISCOMs containing antigen are rapidly taken up by antigen presenting cells 
and induce inflammatory cytokines and CTL response. ISCOMs have been successfully 
integrated into several veterinary vaccines sold in Sweden including those for canine 
lyme disease, feline leukemia and equine influenza with no adverse side effects45. 
ISCOMs have been studied in a range of animal models and have been found to 
promote both a humoral and cell-mediated immune response45. It is currently unknown 
whether this success can be reproduced in humans45. Matrix-MTM, a human vaccine 
containing ISCOMs, is currently in clinical trials46.   
2.5.4 Microorganism-derived Adjuvants  
The natural immune stimulating properties of microorganisms make them 
suitable candidates for vaccine adjuvants. An intact microorganism is too toxic for 
immunization, but several microbially-derived products have been successfully 
incorporated into vaccines. The TLR4 agonist, lipopolysaccharides (LPS), found in the 
outer membranes of gram-negative bacteria, can elicit a potent immune response. 
Monophosphoryl lipid A (MPLA), a derived form of LPS, sacrifices immunogenicity for a 
relatively lower toxicity. AS04, a formulation containing MPLA and alum, has already 
been licensed by several regulatory agencies in Europe and Australia47. 
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Artificially prepared liposomes comprised of lipid bilayers were introduced in the 
1960s as models for lipid bilayer membranes in cells36. In the 1970s they were 
proposed as adjuvants that could encapsulate antigen and fuse with target cells36,40. 
Mechanisms of adjuvanticity include carriers of antigen, depots for sustained release of 
antigen and targeting of APCs36. The potency of liposomes can be modified by varying 
the number of lipid layers, their charge, and composition40. Liposomes have been 
shown to safely induce antibody responses against poorly immunogenic proteins36. 
Several obstacles for the use of liposomes in vaccine formulations include stability, 
manufacturing and quality assurance40.  
Nucleic acid-based adjuvants include CpG motifs which are PAMPS that are 
abundant on microbial genome40. CpG motifs are short DNA sequences that contain a 
cytosine triphosphate deoxynucleotide followed by a guanine triphosphate 
deoxynucleotide that can be immunostimulatory depending on the cytosine’s 
methylation state40. CpG motifs are TLR 9 agonists that can induce secretion of IFN-
alpha, IFN-beta and IL-12 cytokines and elicit a Th1 response40.  Deoxynucleotide and 
DNA vaccine vectors with one or more CpG motifs may benefit from a higher immune 
enhancing potential. Several experimental vaccines including CpG motifs are currently 
being evaluated for viral and cancer infections40. There are considerable concerns 
about the safety of CpG motifs due to dose toxicity40. 
2.5.5 Virosomes and Virus-like Particles 
In 1975, viral envelope proteins were integrated into liposomes, leading to the 
development of the first virosome47. In addition to the advantages of liposomes, 
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virosomes have antigens on the surface. These antigens are either virus-derived or 
recombinant membrane proteins and most commonly hemagglutinin (HA) and 
neuraminidase (NA) from the influenza virus40,48. Viral glycoproteins can stimulate a 
strong antibody response and fusion of the virosome with an endosomal membrane 
primes a cytotoxic T-lymphocyte response through MHC class I presentation. Several 
experimental influenza A vaccines adjuvanted by virosomes have had success in 
establishing protective immunity. 
Virus-like particles (VLP) which are mistaken by the immune system as authentic 
virions can elicit a potent immune response against displayed antigen49. VLPs consist of 
a hollow capsid completely lacking genetic material making them replication 
incompetent40. A VLP vaccine for the human papilloma virus (HPV) consisting of 
recombinant VLPs of HPV 6, 11, 16 and 18 has been approved for clinical use by the 
FDA40. VLPs have the ability to stimulate an effective humoral and cell-mediated 
response. This may be due to the particulate VLP structure that is easily uptaken by 
antigen-presenting cells and can prime lasting antibody and cytotoxic T-lymphocyte 
responses49. Future VLPs may contain DNA or other treatments rather than being 
empty vesicles49.  
2.5.6 Cytokines 
Several cytokines have been evaluated for their adjuvant properties, including IL-
2, IL-12, IFN-gamma and GMC-SF. A primary advantage of cytokines is that ability to 
modulate an immune response towards a Th1 or Th2 response50.  Cytokines are ideal 
for DNA vaccines that can express the cytokine alongside the antigen40. An 
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experimental vaccine against Streptococcus pneumoniae showed increased protection 
with the inclusion of IL-1250. The dose of cytokines is critical and too much of a cytokine 
can be highly toxic51. For example, high doses of IL-2 and IFN-gamma can induce 
autoimmune disease or have a suppressive effect respectively52.  
2.6 Polymeric Adjuvants 
Polymers can deliver antigen in multiple forms including nanoparticles, matrices 
or micelles, and offer many advantages over more traditional adjuvants discussed 
earlier. They have the potential to sustain the release of antigen over a period of time 
which could eliminate the need for booster shots, a concern especially in developing 
countries, making them the best option for single dose vaccines3,53. Some polymers 
may interact and active PRRs to initiate an innate immune response53. Polymeric 
adjuvants can also be further tailored to incorporate additional immunomodulatory 
properties. 
Antigen can loaded into polymers through several different methods which 
include entrapment, surface chemical conjugation and physical adsorption. Entrapment 
in particulates is most common and may help to preserve the activity of the antigen. 
However the antigen could also be compromised through the encapsulation process or 
the degradation of byproduct of the polymer54. Antigen entrapment favors a cell-
mediated immune response55. Surface bound antigen supports a humoral immune 
response but chemically binding may provide less protection and not be ideal for the 
presentation of certain epitopes54,55. Physical adsorbing antigen to the polymer surface 
is a less intensive process and data suggests that it may be more effective at boosting 
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an immune response than antigen entrapment54. Ultimately the ideal method of loading 
will depend on the antigen itself and the delivery system.  
2.7 Naturally Occurring/Derived Polymers 
Several naturally occurring and derived polymers originating from plants and 
microbes have been included in experimental vaccines due to their adjuvant properties. 
These polymers have the added benefit of being biodegradable, cheap, non-toxic and 
eco-friendly56.  
2.7.1 Chitosan 
Chitosan is a linear polysaccharide comprised of randomly distributed -linked D-
glucosamine and N-acetyl-D-glucosamine. Chitosan is derived from the deacetylation of 
chitin found in the exoskeletons of crustaceans, the most abundant biopolymer after 
cellulose57. The degree of deacetylation affects the pKA value of its primary amine 
groups and influences the solubility, chain conformation and electrostatic properties of 
chitosan57. Chitosan forms water soluble salts in acidic aqueous media with protonated 
amine groups58. The large molecular weight, positive charge and gelation 
characteristics of chitosan attribute to the many applications of the polymer in fields 
including agriculture, textiles, cosmetics and food processing57,58. The polymer improves 
transport across mucosal membranes and has been widely studied for the nasal 
delivery of antigens. This mechanism is thought to be a combination of mucoadhesion 
and an ability to open tight junctions in cell membranes58. Chitosan antigen delivery 
systems include aqueous dispersions, gels, sponges and micro/nanoparticles59. 
Possible modes of adjuvanticity include the recruitment and activation of macrophages 
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and the induction of cytokines including IL-2, IL-10, IL-21, TNF-alpha and IFN-gamma57. 
Advantages of chitosan include immunostimulation, biodegradability, bioadhesion and 
penetration enhancing properties57. Chitosan may one day provide a suitable delivery 
system for mucosal immunizations57.  
2.7.2 Alginate 
Alginate is an unbranched polysaccharide that contains blocks of (1,4)-linked -
D-mannuronate (M) and -L-guluronate (G) residues60.  Alginate is a component of 
algae such as kelp and can be extracted by treatment with aqueous alkali solutions. 
After precipitation, water soluble sodium alginate is produced61. The source of the 
alginate determines the M/G ratio and thus affects its physiochemical properties such as 
release kinetics and phase behavior61. Adding a sufficient quantity of calcium ions to 
sodium alginate causes a precipitate of calcium alginates62. When brought to the verge 
of a gel phase, a mixture of suspended antigen and sodium alginate can form a gel 
depot after administration due to calcium present in living tissue63. Alginate- based 
vaccine delivery systems have been safely administered orally to several animal 
species including cattle, rabbits and mice64. Antibody titers of animals administered 
sodium alginate are as good as or better than Freund's adjuvant62.  
2.7.3 Dextran 
Dextran is a complex, branched polysaccharide containing a linear backbone of 
-linked D-glucopyranosyl units.  This biopolymer is synthesized by special lactic acid 
bacteria from sucrose and secreted to modulate adhesion. Dextrans have a high water 
solubility, and controlled degradation yields dextran of a wide range of molecular 
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weights65.  Several derivatives of dextran have been evaluated for their adjuvant 
properties. Dextran sulfate has been effectively used as a matrix material for the 
controlled release of pharamceuticals66. It has a high charge density due to a high ratio 
of negatively charged sulfate to glucosyl residues which can increase loading of 
positively charged drugs such as doxorubicin66. Higher molecular weight 
diethylaminoethyl (DEAE) dextran is a polycationic polymer of dextran that has been 
applied to vaccines for foot-and-mouth disease and Venezuelan equine 
encephalomyelitis in mammals67.  Additionally acetylated dextran in the form of 
microparticles have been explored as delivery platforms for vaccines. These 
microparticles are water insoluble but degrade quickly in acidic environments such as 
lysosomal vesicles due to acetal hydrolysis68. Acetylated dextran does not degrade into 
acidic byproducts which may be harmful to antigen68.  
2.7.4 Starch 
Starch are polysaccharides consisting of a large number of glucose residues 
linked together with -D-(1-4) and/or -D-(1-6) linkages. Starch typically consists of 
amylopectin branched linkages and 15-20% amylose linear structures56. Starch is water 
soluble after hydrolysis by an acid or enzyme and can be cross linked into 
biocompatible particles for antigen delivery that are readily taken up by macrophages69. 
It is attracting interest as an adjuvant due to a large variety of protein antigens that are 
not denatured in the presence of starch56,70. A limitation of starch is its high 
susceptibility to acid degradation however it can be modified to impart acid-resistance56. 
By far the most popular starch adjuvants are polyacryl starch microparticles. These 
starch microspheres are typically 1-3 m in diameter and covalently conjugated with 
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antigen69,71. Polyacryl starch microparticles have been shown to induce mucosal and 
systemic immune responses in mice when administered orally69,71. Experimental 
polyacryl starch vaccines against diphtheria and  Salmonella enterica serovar Enteritidis 
have shown enhanced immune responses in mice72–74. 
2.8 Synthetic Polymers 
Synthetically-derived polymers provide a number of benefits over naturally 
occurring polymers.  These materials can be easily modified to change the payload 
release kinetics, hydrophobicity, surface charge, or other properties that may benefit a 
vaccine formulation. The precursors of synthetic polymeric adjuvants are unlikely to 
contain reactive or allergenic epitopes34. In addition to the synthetic polymers listed, 
polycaprolactones, polyelectrolytes, polyphosphazenes, polymethacrylates and 
polyvinylpyrrolidone have all been studied as potential vaccine adjuvants53.  
2.8.1 Polystyrene 
Polystyrene made up of synthetic styrene monomer has been shown to have 
immunostimulatory properties in the form of  solid inert nanobeads with antigen 
adsorbed on their surfaces75. There is evidence to suggest that the size of these 
nanobeads may direct the type of immune response76. Nanobeads between the size of 
40-50 nm are more readily taken up by APCs and induce strong cell-mediated immune 
responses whereas larger nanobeads induce higher antibody titers75. The conjugation 
of multiple peptides to polystyrene nanobeads is a possibility for protecting against 
highly variable pathogens75. Nanobead therapies have been used successfully in 
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experimental veterinarian and administered mucosally and parenterally for DNA 
immunizations resulting in better responses than DNA alone19.  
2.8.2 Polyesters 
The most widely used class of polymeric adjuvants are polyesters.  Of these, 
poly lactic co-glycolic acid (PLGA) copolymers are the most common carriers for 
antigen delivery68. This commercially-available, biodegradable polymer produces lactic 
acid and glycolic acid end products which are easily metabolized, making this a safe, 
biocompatible polymer platform.  It is approved for parenteral drug delivery by both FDA 
and European Medicine Agency77. PLGA is negatively charged with a degradation 
profile that varies with molecular weight and copolymer ratios77.  Encapsulated drugs 
widely vary in size and polarity and leading to numerous antigens that have been 
successfully incorporated into PLGA nanoparticles77. PLGA particles have shown a high 
encapsulation efficiency of around 60 to 70% but low drug loading of approximately 
1%77. Studies have shown that these particles may enhance both a cell-mediated and 
humoral immune response78. A limitation of PLGA is that vaccine preparations can 
require high shearing and organic solvents that can compromise antigen integrity57. In 
addition the byproducts of PLGA, lactic and glycolic acid, create an acidic 
microenvironment during degradation which could compromise the stability of the 
loaded protein68. Polyactide (PLA) micro and nanoparticles have used in several 
experimental vaccine formulations78–81. 
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2.8.3 Polyanhydrides 
Another class of polymers that has been reported to successfully adjuvant 
several protein vaccines are polyanhydrides. This polymer class is characterized by its 
anhydride bonds, and undergoes base-catalyzed hydrolysis to produce biocompatible, 
non-toxic degradation products. A copolymer of two anhydrides, p-carboxyphenoxy 
hexane and sebacic acid, has been FDA approved for human use in the Gliadel wafer, 
a post-surgical anti-cancer cranial implant82. Polyanhydrides are delivered in the form of 
nanoparticles or microparticles with encapsulated payload. These particles have 
encapsulation efficiencies similar to PLGA with a significantly lower burst release. 
Unlike polysesters, polyanhydrides degrade via a surface erosion mechanism which 
leads to near zero-order release kinetics83. This degradation profile is controllable by 
varying the polymer chemistry and potentially allows the formulation of single dose 
vaccines.  Like polyesters such as PLGA, some polyanhydride chemistries can produce 
locally acidic microenvironments, which can lead to protein degradation84. 
2.8.4 Non-ionic Block Copolymers 
Poloxamers and poloxamines are non-ionic block polymers of hydrophobic 
polyoxypropylene (POP) and hydrophilic polyoxyethylene (POE) that exhibit 
temperature and pH-sensitivity85. Copolymers with less than 10% POE content 
spontaneously assemble into micelles, 300 nm – 3 µm, in aqueous solutions at 
physiological pH86.  It has been suggested that copolymers with low hydrophile–lipophile 
balance may destabilize the plasma membrane of APCs allowing antigen to channel 
into MHC class I pathway essential for cell-mediated immunity85. Nonionic copolymers 
with 10% POE content significantly augment Type 2 T- helper T-lymphocyte responses 
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while polymers between 5-10% POE content augment both Type 1 and Type 2 
responses86. Several poloxamer and poloxamines have proven to be powerful vaccine 
adjuvants with low POE content, 5-10%, and a molecular size of 11-12 kDA85.  Block 
copolymers with longer POP chains induce higher concentration of antibody isotypes 
associated with protective immunity in many viral and bacterial infections87. Non-ionic 
block copolymers are not biodegradable.  
Poloxamers consist of a central chain of hydrophobic POP bordered by 
hydrophilic chains of POE.  Poloxamers were introduced in the 1950s under the trade 
name Pluronic and include a family of more than 50 block copolymers in a range of 
liquids, pastes and solids85. Neutrally charged poloxamers condense and encapsulate 
through the formation of micelles at relatively low concentrations above their critical 
micellar concentration88.  Incorporation of dimethylaminoethyl methacrylate allows the 
condensation of plasmid DNA through electrostatic interactions88. Poloxamers have 
been shown to enhance in vivo and in vitro transfection efficiencies88.  The polymeric 
adjuvant CRL1005, a widely studied poloxamer, has been shown to enhance the 
expression of antigen in vivo88. A pentablock copolymer platform based on poloxamer 
407 shows potential as a vaccine adjuvant that can co-deliver protein and DNA in a 
sustained fashion89. 
Poloxamines, trade name Tetronic, are nonionic block copolymers similar in 
chemistry to poloxamers. Poloxamines have are tetrafunctional X-shaped block 
copolymers with four POP-POE blocks bonded to a central ethylenediamine moiety. 
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Poloxamines have similar properties as poloxamers but are less studied as vaccine 
adjuvants. 
2.9 Tailoring Polymer Chemical Properties 
The ability to easily modify properties to suit a particular antigen is a unique 
advantage of polymeric adjuvants. Minor differences in parameters can greatly affect an 
immune response57. The size of the polymeric particles affects both tissue and cellular 
uptake111. Nanoparticles are more effective in targeted delivery systems due to their 
ability to pass through biological barriers and capillaries after administration54. 
Nanoparticles are also more efficaciously phagocytosed by APCs. It has been reported 
that cellular uptake of nanostructures is 15-250 times greater than microparticles54,111. 
Particles 500 nm or less are optimal for uptake by APCs. These particles may escape 
from endolysosomal compartments into the cytosol, leading to a cell-mediated immune 
response.  Particles greater than 500 nm are uptaken by APCs via phagocytosis or 
micropinocytosis and may generate a humoral immune response54.  
The surface charge affects interactions with cells and can be tailored to increase 
cellular uptake. Positively charged particles increase internalization though ionic 
interactions with negatively charged cell membranes77. These particles are also more 
capable of escaping lysosomes and exhibit perinuclear localization77. Negatively and 
neutrally charged particles are more likely to colocalize with lysosomes77. Positively 
charged surfaces can allows interaction with exogenous nucleic acids for DNA delivery, 
negatively charged mucosal surfaces or plasma membranes57. 
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The effectiveness of an adjuvant is also dependent on hydrophobicity or 
hydrophilicity. Hydrophobic particles are identified by the body as foreign, and enhance 
cell adhesion and phagocytosis of macrophages77,112. Increasing the hydrophobicity of 
polymer adjuvants generally results in an increase of adjuvant effect but can also impact 
biodegradation and solubility 112.  
The release profile of a particular polymer platform can be tailored by changing 
the molecular weight or chemical properties. The rate of hydrolysis (i.e. chemical 
breakdown due to a reaction with water) of PLGA is dependent on the ratio of lactic to 
glycolic acid and or molecular weights113. Modifying this ratio can change the rate of 
hydrolysis of PLGA from a few days or weeks, to months or a year113. The desire for 
short bursts of antigen or continuous release may be dependent on if the memory cells 
are long-lived or need re-stimulation78.  
2.10 Polymer Functionalization 
In addition to controlling the chemical properties, polymers can be functionalized 
to improve adjuvanticity. Popular functionalization methods include modification with 
other polymers, conjugation of microbially-derived antigen and carbohydrates. A simple 
modification of structure can affect targeting, catalysis, signaling, catobolism, 
immunogenicity and circulation114.  
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2.10.1 Modification with Other Polymers  
PEG is a hydrophilic and non-ionic polyether compound that is biocompatible and 
FDA-approved for various applications77,114. PEGylation is the modification of a 
molecule by linking one or more chains of polyethylene glycol (PEG)114. This method 
was discovered in the 1970s by Davies and Abuchowsky with the covalent attachment 
of PEG chains to both albumin and catalase through amino groups115,116. The 
conjugation of PEG to thiol, hydroxyl and amide groups is now possible via a multitude 
of chemical and enzymatic reactions114. Surface modification with PEG can provide a 
hydrophilic layer that increases the blood circulation half-life by several orders of 
magnitude77. Surface modification with PEGylation can provide a hydrophilic layer that 
increases the solubility of complexes, minimize aggregation and reduce interactions 
with proteins in physiological fluids77,117. This can increase the blood circulation half-life 
of PEGylated polymers by several orders of magnitude77. The PEGylation of chitosan, 
PLGA, poloxamers and poloxamines have all been studied77. An increase in PEG 
molecular weight in PLGA nanoparticles leads to less interaction with phagocytic cells 
and longer systemic circulation118 PEG functionalized nanoparticles are often called 
“stealth nanoparticles” due to their ability to evade the immune systems defences118.   
Modification with chitosan, poloxamines and poloxamines can deter hydrophobic 
and electrostatic interactions that assist in opsonination77.  Poloxamer and poloxamine 
block copolymers adsorb strongly to the surface of hydrophobic nanospheres85. Surface 
modification with poloxamer and poloxamine block copolymers can also increase 
systemic circulation times. Polystyrene and PLGA nanoparticles coated with poloxamer 
407 and poloxamine 908 leads to a reduction of capture by macrophages in vitro and in 
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vivo and extends blood circulation times119.A chitosan coating can shift surface charge 
towards neutral77. The surface modification PLGA nanoparticles with chitosan results in 
increased penetration of mucosal surfaces, a higher zeta potential and increased 
encapsulation efficiency of tetanus toxoid protein118.  
2.10.2 Attachment of APC Specific Antibodies for Increased Targeting  
Targeting APCs is an emerging antigen delivery strategy with extraordinary 
potential. This can be accomplished by functionalizing polymers with APC specific 
antibodies. In most ideal cases, antigen is taken up by peripheral immature dendritic 
cells in the skin which mature and migrate to the lymph nodes where they activate T 
lymphocytes120. This can be challenging due to the extremely low number of dendritic 
cells in the skin and the high chance of free antigen being ingested by other cells 
types120. Kawon et al. conjugated dendritic cell specific antibody anti-Dec205 onto 
microparticles and demonstrated increased uptake of antigen in vivo. The conjugated 
microparticles were significantly more likely to be endocytosed by dendritic cells than 
control particles121. Vaccines that target immature dendritic cells within lymph nodes 
could also potentially induce self-tolerance to antigens involved in autoimmune 
disease120.    
2.10.3 Bioconjugation of PAMPs for Pathogen Mimicking Behavior  
PAMPs are often made up of carbohydrates including glucans, mannose and 
fructose structures that are constituents or expressed by viruses, fungi and bacteria29. 
Carbohydrates can target and stimulate antigen presenting cells via c-type lectin 
receptors3. Macrophages and immature dendritic cells express macrophage mannose 
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receptor (MMR) which contains multiple carbohydrate-binding domains122. Targeting to 
the MMR is expected to be beneficial in eliciting protective immunity122.  There are 
polymers of mannose and Jl-3 glucose which have been proposed as vaccine 
adjuvants3. In addition, carbohydrates can be anchored to polymers to enhance their 
adjuvanticity. These modified polymers are essentially pathogen-mimicking and can 
improve vaccine formulations through increased activation of antigen presenting cells.  
An example of carbohydrate modified polymeric adjuvants is mannose functionalized 
pentablock copolymer based on poloxamer 407 through an azide-alkyne click reaction. 
LPS is a major constituent of the outer membrane of gram-negative bacteria that 
binds to TLR4 PRRs. Isolated LPS can induce very potent immune response but often 
at the expense of low toxicity. These microorganism-derived adjuvants can be 
incorporated into existing polymeric adjuvants at safe levels for a boost in adjuvanticity. 
The conjugation of LPS to the non-ionic block copolymer L141 showed a markedly 
reduced toxicity possibly due to sequesteration of LPS under the liposomal surface87. 
Lipid A analogs can be encapsulated with vaccine particles as an alternative to 
conjugation. Mice orally administered with PLGA nanoparticles encapsulated with MPLA 
and OVA produced higher antigenic specific IgG and IgA antibodies in comparison to 
control formulations123. TLR ligands have also been included in polymeric vaccine 
formulations and co-delivered with antigen124.  
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2.11 Conclusions 
Despite great advances in immunology, commercial vaccine design has 
remained nearly unchanged for over a century. Aluminum salts are still the most 
commonly used vaccine adjuvant, with only a handful of additional adjuvants currently in 
use. It is widely accepted that the immune system responds to each pathogen in a 
unique manner according to its properties. The innate immune system recognizes 
specific, conserved pathogen-associated molecular patterns using pattern recognition 
receptors on immune cells. However the immune responses generated may differ 
based on the PRR that is activated, leading to different downstream signaling cascades 
which can have a great effect on the immune response. One pathogen may elicit a 
cytotoxic T cell response while another may generate an antibody-mediated immune 
response. Each may provide optimal protection upon reinfection with a given pathogen. 
It is therefore necessary to rationally design a vaccine in order to train the immune 
response to best respond to a given pathogen.  
Many novel vaccine adjuvants have been reported in the literature. These include 
pathogen-derived molecules such as LPS, MPLA, viral DNA, and pathogen-inspired 
structures such as virus-like particles. Of these, only a few have been approved for 
commercial use. Additionally, small molecule-type adjuvants do not provide a delivery 
system for antigen, and may require a multiple dose regimen to be effective at 
establishing long-term immunity. Polymeric vaccine adjuvants can be easily modified to 
reflect the properties of a pathogen and train the immune system to respond 
appropriately. By tailoring molecular weight, surface charge, hydrophobicity and 
degradation kinetics, polymeric vaccine adjuvants may be rationally designed to elicit an 
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optimal memory immune response. Naturally derived polymeric vaccine adjuvants have 
the advantage of being largely biocompatible and widely available, but can be difficult to 
modify easily. Synthetic polymers are easily modified, but many vaccines are difficult to 
manufacture without subjecting antigens to harsh solvents and conditions. 
Polymeric adjuvants can also be modified with small molecular weight polymers 
such as     polyethylene glycol, microbial derived compounds or PRR-targeting sugars 
to increase immunogenicity or attempt to target specific cell types. It has been reported 
that functionalization with PEG can change the surface potential of a vaccine adjuvant 
and have a great effect on the properties and cellular interactions. Additionally, a 
polymeric vaccine, which has the potential to allow for controlled release of antigen, 
may be functionalized with one of the numerous reported microbially-derived adjuvants 
to direct the immune response to respond favorably to infection with a given pathogen.  
Finally, polymeric vaccine adjuvants and antigen delivery systems may be modified so 
as to target specific immune cells such as macrophages or dendritic cells.  There are 
many options available to tailor an effective immune response to a specific pathogen.  
The next generation of vaccine adjuvants must be based on immunological principles to 
control the immune response to elicit protective immunity. 
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Figure 1: Polymeric adjuvant antigen loading 
 
Figure 2: Polymeric adjuvant functionalization 
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Tables 
Table 1: Vaccine categories 
Vaccine Type Definition Advantages Disadvantages 
Live, 
attenuated 
organisms 
A whole 
replication-
competent  
microorganism 
attenuated in 
pathogenicity 
Generally 
more potent, 
longer lasting 
protection; 
fewer 
inoculations 
Potential safety risks 
to 
immunocompromised 
recipients. The 
pathogen can revert 
back to a virulent 
state.  
Inactivated or 
killed 
A whole 
replication- 
incompetent 
microorganism 
Safer than live 
vaccines; 
longer shelf 
life 
Lack potency of live 
vaccines; does not 
elicit an effective cell-
mediated immune 
response 
Subunit A protein or 
genetic material 
expressing 
antigen from a 
microorganism 
Generally less 
reactogenic, 
DNA-based 
can elicit cell-
mediated 
immune 
response 
Protective antigen 
must be known; 
Requires right 
adjuvant for potency 
 
Table 2: Polymeric adjuvants and their chemical properties. 
 Molecular Structure Common 
Properties 
Antigen 
Chitosan  
 
 
 
Particles / 
Matrix58, 
Cationic58, 
50 kDa – 
2000 
kDa58, 
Mucoadhe
sive 
properties5
8
 
Tetanus toxoid90, 
Diphtheria 
toxoid91 
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Table 2 continued 
Alginate -L-guluronate  
 
-D-mannuronate 
 
Matrix61, 
Anionic61, 32 
– 400 kDa61, 
Strong 
humoral 
response92 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tetanus 
toxoid93, 
rotavirus94, 
Salmonella 
typhi63 
Dextran  
 
Particles68, 
Encapsulate
d antigen, 
Non-ionic95, 
1kDa65 
 
 
 
 
 
 
 
Killed listeria 
monocytogenes
96
, 
Mycobacterium 
tuberculosis 
antigen97, 
Tetanus toxoid98 
 
 
 
 
Starch -D-glucose 
  
 
Particles69, 
Encapsulate
d antigen, 
Nonionic and 
ionic starch 
derivatives69 
 
 
 
 
 
 
Diphtheria 
toxoid72, 
Salmonella 
enterica serovar 
Enteritidis 
flagellin73 
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Table 2 continued 
Polystyrene  
 
 
 
Particles, 
Surface 
attached 
antigen75,76, 
Non-ionic 
 
 
 
 
 
Model 
ovalbumin 
antigen99 
PLGA Poly(lactic acid) LA 
 
Poly(glycolic acid) GA 
 
Particles, 
Encapsulat
ed antigen, 
Anionic 
Boophilus 
microplus 
SBm7462100, 
Diphtheria 
toxoid101, HIV-1 
gp12081, 
Malaria 
synthetic 
peptide 
SPf66102, 
Tetanus 
toxoid103,mycob
acterial hsp65-
DNA104 
Polyanhydride 1,6-bis(p-carboxyphenoxy)hexane 
(CPH) 
 
Sebacic acid (SA) 
 
1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane (CPTEG) 
 
Particles, 
Encapsulat
ed antigen, 
Anionic, 5 
kDa – 15 
kDa 
Bacillus 
anthracis 
Antigen105, 
pneumococcal 
surface protein 
A106, Yersinia 
pestis antigen107 
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Table 2 continued 
Non-ionic 
Block 
Copolymers 
Polyoxypropylene 
 
 
Polyoxyethylene 
 
Micelles / 
Matrix, 
Amphiphili
c, 5 kDa – 
15 kDa85 
Anthrax 
recombinant 
protective 
antigen108, 
Diphtheria 
toxoid108, HIV-1 
gp140-DNA109, 
Leishmania 
major gp6389, 
Tetanus toxoid110 
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3.1 Abstract 
We report a new catalyst for atom transfer radical polymerization (ATRP) for the 
synthesis of copper-free poly(2-diethylaminoethyl methacrylate (PDEAEM)-based 
pentablock copolymeric biomaterials that have been shown to be effective gene delivery 
vectors. Biocompatibility is an increasing concern with growing applications for 
functional polymers because of the residual soluble copper salts used as catalysts. The 
reported ATRP synthesis method utilizes novel copper(I) oxide nanoparticles as 
catalysts, that can be easily removed after polymerization with x-ray spectroscopy 
(XPS) showing no residual copper in the final product with potential applications in drug 
and gene delivery.  
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3.2 Introduction 
Atom transfer radical polymerization (ATRP) has been used as an effective 
method for controlled synthesis of a wide range of polymers and copolymers.[1] The 
controlled radical polymerization reaction is a multicomponent system consisting of an 
initiator, monomer and a catalyst composed of a transition metal species with a suitable 
ligand.[2] The synthesized polymers have high degrees of polymerization, narrow molar 
mass distributions and advanced macromolecular architectures such as block 
copolymers.[3] The transition metal catalyst plays an essential role in ATRP reactions as 
it controls the equilibrium between propagating and non-propagating polymer chains.[4] 
The most common transition metal used is copper(I), in the form of copper salts in part 
due to its versatility and low cost. [2, 3] 
The use of soluble copper in ATRP reactions has limitations when designing 
polymers for biomedical applications, as the copper must be removed before use.[5] The 
presence of copper has been shown to have cytotoxic effects when administered to 
cells in vitro.[6] The traditional soluble Cu(I) catalyst is very difficult to remove from 
polymers synthesized through ATRP reactions, which limits any potential use of the 
polymer synthesized by ATRP in biomedical applications.[5,7,8,9] Here we report a novel 
method for the ATRP synthesis that overcomes these drawbacks using cuprous oxide 
nanoparticles as catalysts. These nanoparticles can be easily removed after the 
polymerization reaction compared to the soluble copper salts currently used. While 
cuprous oxide nanoparticles have been recently shown to catalyze azide-alkyne click 
reactions,[6] they have not been used in the past for ATRP synthesis. 
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We have designed and synthesized pentablock copolymers based on PDEAEM 
and Pluronic blocks that exhibit pH and temperature sensitive gelation behavior. [10,11,12] 
These block copolymers are very effective injectable sustained gene delivery vectors. 
[13,14,15,16]
  Until recently, the formation of pentablock copolymers from Pluronic 
macrointiator required the use of soluble copper(I) bromide as a catalyst for the ATRP 
reaction.[12] The copper(I) bromide required an intricate removal process that left 
residual copper and ultimately increased the cytotoxicity of the polymers as compared 
to Pluronic.[5,12] We have shown that cuprous oxide nanoparticles are able to 
successfully catalyze the ATRP polymerization of diethylaminoethyl methacrylate 
(DEAEM) outer blocks starting with a macroinitiator Pluronic F127 to form the previously 
reported PDEAEM pentablock copolymers.[12] The reaction schematic of the synthesis 
of the PDEAEM pentablock copolymer with the cuprous oxide nanoparticles is 
illustrated in Figure 1. The reaction was performed using the same amount of copper as 
previously described; however the cuprous oxide nanoparticles were shown to be easily 
removed using a column of basic alumina. In addition, the block copolymers were found 
to have a significantly lower cytotoxicity when synthesized with the cuprous oxide 
nanoparticles. 
3.3  Experimental Section 
3.3.1 Reagents 
N,N-(diethyl amino)ethyl methacrylate (DEAEM), polyvinylpyrrolidone (Mn = 
40000) and Pluronic F127 (Mn = 12600, 70% PEO) were purchased from Sigma-Aldrich, 
St. Louis, MO. Copper acetate, sodium borohydride, toluene and all other chemicals 
were purchased from Fisher Scientific, Pittsburgh, PA. The synthesis of N-propyl-
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pyridynyl methanimine (NPPM) from 1-propylamine and 2-pyridinecarbaldehyde has 
been previously described and its use in ATRP was first reported by Haddleton and 
coworkers. [12]  
3.3.2 Synthesis of Copper(I) Oxide Nanoparticles 
The preparation of cuprous oxide nanoparticles has been previously described 
by Zhang et al.[6] Briefly, two solutions were prepared for the synthesis of cuprous oxide 
nanoparticles. The first solution consisted of copper acetate (.4g, 2.2mmol) in 20 mL of 
water. The second solution contained sodium borohydride (.76g, 20 mmol) and 
polyvinylpyrrolidone (1.6g, 40 kDA) in 200 mL of water. The solutions were carefully 
combined and reacted at 20°C under constant stirring. After 3 hours the resulting 
solution was centrifuged at 15180xg. The colorless supernatant was discarded and the 
black pellet of aggregated cuprous oxide nanoparticles was dried overnight in a vacuum 
oven. The cuprous oxide nanoparticles were used at a concentration of 4.8 mg/mL for 
the polymerization reaction. 
3.3.3 Characterization of Copper(I) Oxide Nanoparticles 
The cuprous oxide nanoparticles were characterized to determine size and 
morphology using a field emission scanning electron microscopy (FE-SEM; FEI Quanta 
250). 
3.3.4 Synthesis of Pluronic Macrointiator 
The synthesis of difunctional 2-bromo propionate Pluronic F127 macrointiator 
has been previously reported by our group.[12] Briefly, Pluronic F127 (40 g, 3.2 mmol) 
was dissolved in tetrahydrofuran in a large round-bottom flask. Triethylamine (20 mL, 
143 mol) and 2-bromoisobutyryl bromide (3 mL, 24 mmol) were added to the reaction 
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flask. The reaction flask was left in an ice bath and the reaction proceeded for at least 
20 hours. Excess solvent was removed with a rotary evaporator and the Pluronic 
macrointiator was precipitated out in chilled n-heptane.    
3.3.5 Synthesis of Pentablock Copolymers using Copper(I) Bromide 
A copper(I) bromide solution (.24 g, 1.67 mmol) dissolved in 50 mL of toluene 
was prepared in a round-bottom flask. Pluronic macrointiator (10 g, 0.78 mmol) and a 
magnetic stir bar were added before a rubber stopper was securely fitted with a cable 
tie. To remove air the reaction flask was degassed by vacuum-argon three times. The 
NPPM ligand [.5 mL, 3.40 mmol] and DEAEM monomer [4 mL, 2.53 mmol] were added 
using a glass syringe to the reaction flask and the solution turned a dark orange brown. 
Several freeze-pump-thaw cycles with liquid nitrogen were used to further remove 
oxygen until the evolution of gas from the solvent was no longer visible. A small volume 
of inert gas was added and the reaction flask was reacted in a water bath at 70°C and 
300 RPM. To study polymerization propagation samples were taken at timed intervals 
with great care taken to not introduce air into the reaction flask. After 20 hours the 
reacted product was passed through a column of basic alumina with a 1:1 
dichloromethane:toluene solution to remove the cuprous bromide which left behind a 
wide bluish green band. The collected polymer was precipitated in chilled n-heptane 
after a rotoevaporator was used to reduce the volume of solvent. The precipitated 
produced was collected using a Büchner funnel and left in a vacuum oven to dry.  
3.3.6 Synthesis of Pentablock Copolymer using Copper(I) Oxide Nanoparticles 
The reaction conditions between the cuprous bromide and cuprous oxide 
catalyzed pentablock copolymer synthesis are identical except where noted.  The 
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solution of cuprous oxide nanoparticles (.24 g, 1.68 mmol) in toluene was briefly 
sonicated in a round-bottom flask before adding the reactants and ligand, as described 
above. After 20 hours the reacted product was passed through a column of basic 
alumina with a 1:1 dichloromethane:toluene solution. The cuprous oxide nanoparticles 
stayed mostly aggregated upon removal at the head of the column leaving behind a 
narrow darkly colored band. The polymer was collected, excess solvent removed, and 
precipitated as described for the copper(I) bromide synthesis and dried overnight before 
characterization.  
3.3.7 Characterization of Pentablock Copolymers 
The pentablock copolymers were characterized using 1H NMR spectra gathered 
from a Varian VXR-300 MHz NMR spectrometer with deuterated chloroform as solvent. 
The average molar mass and dispersity were calculated using a Dawn Heleos light 
scatter from Wyatt Technology at 25°C with THF as the mobile phase. The refractive 
index increment, dn/dc, for the pentablock copolymers was found to be 0.0513 ml/g. 
3.3.8 X-ray Photoelectron Spectroscopy (XPS) 
To investigate the residual copper in the polymers, XPS studies of samples were 
performed on a PHI 5500 Multi-technique electron spectrometer. 
3.3.9 Cytotoxicity Assay 
The cytotoxicity of the pentablock copolymers was examined by using the 
commercially available CellTiter 96® Non-Radioactive Cell Proliferation Assay 
(Promega, Wisconsin, United States). EL4 C57BL/6 mice lymphoma cells were plated 
at a concentration of 100,000 cells per mL and incubated in a 96 well plate at 37°C for 
24 hours in a humidified, 5% CO2 atmosphere. Pentablock copolymer was added at a 
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concentration of .5 µg/µL to total volume per well and incubated with the cells at 37°C 
for an additional 48 hours in a humidified, 5% CO2 atmosphere. Untreated sample and a 
sample with 100% lysed EL4 cells were used as negative and positive controls 
respectively. A 15 µL volume of the Promega tetrazolium salt reagent was added to 
each well and the 96-well plates were further incubated at 37°C for 4 hours after which, 
a 100 µL volume of the Promega Solubilization Solution was added into each well. An 
hour later, the absorbance was recorded using a 96-well plate reader at 570nm 
wavelength and a subtracted 690nm reference wavelength.  Corrected absorbance 
values were calculated by subtracting an average absorbance value of 100% lysed cells 
from all other absorbance values.  Cell viability numbers are a fraction of the cells that 
are viable and were calculated by dividing the polymer treated samples‘ corrected 
absorbance value by an average of the non-treated cells’ corrected absorbance value. 
Cell viability confidence intervals for the mean were calculated using propagation of 
error.   
3.4 Results and Discussion 
3.4.1 Synthesis and Characterization of Copper(I) Oxide Nanoparticles 
The cuprous oxide nanoparticles were synthesized from a solution of copper 
acetate (.4g, 2.2mmol), sodium borohydride (.76g, 20 mmol) and polyvinylpyrrolidone 
(1.6g, 40 kDA) in water. After 3 hours, the reacted solution was centrifuged at 10000 
RPM and the black pellet of aggregated cuprous oxide nanoparticles was dried 
overnight in a vacuum oven. The resulting images from scanning electron microscopy 
show the individual nanoparticles at approximately 15 nm in diameter (Figure S1).   
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3.4.2 Synthesis and Characterization of Pentablock Copolymer 
The Pluronic macrointiator and DEAEM monomer were dissolved in toluene 
inside an air free round-bottom flask.  The reaction was catalyzed by the cuprous oxide 
nanoparticles in the presence of the NPPM ligand. The NPPM ligand helps increases 
the activity of the copper(I) catalysts and future work may compare efficiencies between 
NPPM and other ATRP ligands such as1,1,4,7,10,10-Hexamethyltriethylenetetramine 
(HMTETA). [12] The reaction proceeded at 70°C and 300 RPM for 20 hours and then the 
reacted solution was passed through a column of alumina basic. The final product was 
precipitated out with n-heptane and left in a vacuum oven to dry. The 1H NMR spectrum 
of the pentablock copolymer is shown in Figure 2. The peaks demonstrate the purity of 
the final polymer with this new synthesis route with no traces of solvents or ligand. The 
average molar mass and dispersity from several PDEAEM pentablock copolymers 
synthesized from this method were comparable to PDEAEM pentablock copolymers 
synthesized from the previously reported method catalyzed with soluble copper(I) salts 
(Figure 3).[12]  
Monitoring the change of molar mass and dispersity of the block copolymers over 
time of the cuprous oxide nanoparticle catalyzed reaction demonstrated the controlled 
chain growth and narrow distribution of the living polymerization (Figure S2). There was 
an initial induction period, which was attributed to the use of a macrointiator instead of a 
small molecular weight initiator.[12]  
3.4.3 Analysis of Residual Copper in the Block Copolymers 
To determine if there was any residual copper left in the final product, the 
pentablock copolymer was analyzed using XPS before and after column purification. 
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The XPS data from the column purified cuprous oxide nanoparticle catalyzed block 
copolymer shows the removal of two peaks at approximately 935 eV and 955 eV, 
corresponding to copper (Figure 4). XPS data taken from a control cuprous bromide 
catalyzed block copolymer still shows a remaining copper peak at approximately 935 eV 
indicating the presence of residual copper after column purification. 
3.4.4 Cytotoxicity of Copper(I) Oxide Nanoparticle Synthesized Block Copolymers 
The difference in cytotoxicity between the pentablock copolymer synthesized with 
cuprous oxide nanoparticles versus cuprous bromide is statistically significant and 
presented in Figure 5. The cationic outer blocks of the pentablock copolymers 
incrementally add to the cytotoxicity of the pentablock copolymers, so a comparison of 
the block copolymers was done at similar molar masses and at a very high 
concentration to cause cell death.[16]   This difference in cytotoxicity for polymers of 
similar molar masses is presumably linked to the differences in residual copper levels in 
the two polymers, based on differences in the catalysts used. These data correspond 
well to the XPS data presented in Figure 2, showing residual copper in the polymer 
synthesized using soluble copper salts as opposed to the use of cuprous oxide 
nanoparticles as catalysts.  
3.5 Conclusions 
Here we report a novel method for the synthesis of block copolymers using 
copper(I) oxide nanoparticles as the transition metal catalyst for the ATRP reactions. 
The living polymerization can be performed using the same amount of copper as in the 
previously reported method, but now in the form of cuprous oxide nanoparticles instead 
of soluble copper. The polymer structure and purity was confirmed using 1H NMR. The 
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synthesized polymers have a controlled molecular weight and narrow dispersity. 
Analysis by XPS shows no residual copper in the polymer product and the polymers 
had a statistically significant decrease in cytotoxicity. Copper(I) oxide nanoparticles 
have already been proven to successfully catalyze azide-alkyne click chemistry 
reactions.[6] This work reveals the application of cuprous oxide nanoparticles to catalyze 
ATRP reactions. This novel synthesis method has the potential to increase the 
biocompatibility of polymers manufactured through controlled living polymerizations by 
eliminating the need to have soluble copper(I) as a catalyst for the reaction.   
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Figure 1. The ATRP reaction of Pluronic macrointiator with the N,N-(diethyl amino)ethyl 
methacrylate (DEAEM) in the presence of the cuprous oxide nanoparticles and N-
Propyl-pyridynyl methanimine (NPPM) to form poly(2-diethylaminoethyl methacrylate 
(PDEAEM) based pentablock copolymer.  
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Figure 2. 1H NMR spectra of the PDEAEM pentablock copolymer synthesized with the 
cuprous oxide nanoparticles 
 
 
PDEAEM 
Pentablock 
Copolymer 
Catalyst 
 
Mn 
[g mol-1] 
  PDI 
 
     A Cu2O-NP 33120 1.10 
     B Cu2O-NP 48170 1.12 
     C Cu2O-NP 29290 1.26 
     D CuBr 24600 1.16 
     E CuBr 47610 1.15 
     F CuBr 48240 1.16 
 
 
Figure 3. Average molar mass (Mn) and polydispersity indices (PDI) of copolymers 
synthesized using cuprous oxide nanoparticles (Cu2O-NP) and soluble cuprous bromide 
(CuBr) salts. 
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Figure 4. X-ray photoelectron spectroscopy of the PDEAEM-based pentablock 
copolymer before and after column purification. Peaks for copper occur at 
approximately 935 eV and 955 eV, indicated here with black arrows.  
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Figure 5.  The differences in cytotoxicity between the pentablock copolymers 
synthesized using cuprous oxide nanoparticle (Cu2O-NP) and cuprous bromide (CuBr) 
is statistically significant by a one tailed t-test for all cases. All error bars are 95% 
confidence intervals for the mean calculated by propagation of error with a sample size 
of 12. The experiment was independently repeated 5 times with a statistical significance 
between the differently catalyzed pentablock copolymers in each replicate. Letters 
indicate a statistical significance where the P value is <0.05. 
  
68 
 
3.9 Supporting Information 
 

Figure S1.  An SEM image of the cuprous oxide nanoparticles showing size 
 
 
 


 

Figure S2. (a,b) Polymerization propagation of the cuprous oxide nanoparticle catalyzed ATRP 
for block copolymer synthesis showing the average molar mass and dispersity. 
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4.1 Abstract 
We report the synthesis of a family of amphiphilic pentablock polymers with 
different cationic blocks and with controlled architectures as potential vaccine carriers 
for subunit vaccines. The temperature and pH-dependent micellization and gelation of 
these pentablock copolymers can provide a depot for sustained protein and gene 
delivery. The amphiphilic central triblock promotes cellular endocytosis, good gene 
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delivery and has been used effectively as a vaccine adjuvant. The pentablock 
copolymer outer blocks condense DNA spontaneously as a result of electrostatic 
interactions for sustained combinational therapy. This family of polymers with different 
cationic groups was evaluated based on DNA complexation-ability and cytotoxicity to 
select promising candidates as DNA-based subunit vaccine adjuvants. Modification of 
other polymer systems with carbohydrates like mannose has been shown to enhance 
immunogenicity by activating pattern recognition receptors on antigen presenting cells 
and increasing uptake in these cells. Here, we report the synthesis of a virus-mimicking 
pentablock copolymer vaccine platform by successful functionalization of these 
polymers with mannose through an azide-alkyne Huisgen cycloaddition. The synthesis 
of a mannoside with the alkyne linker was achieved by a recently reported bismuth(V)-
mediated activation of a thioglycoside that proved to leave the alkyne intact. The 
carbohydrate modification was shown not to interfere with the ability of these virus-
mimicking block copolymers to complex DNA, thereby making this family of modified 
materials promising candidates for DNA-based vaccine delivery. 
4.2 Introduction 
 Block copolymers based on Pluronics have been used in a variety of 
applications, including sustained drug delivery, therapeutic cellular transfection 
and as novel vaccine adjuvants.1–3 Pluronic F127 is an FDA-approved surfactant 
that exhibits temperature and pH-dependent gelation properties that make it an 
ideal carrier for hydrophobic drugs such as paclitaxel, aspirin and antibiotics.4–8 
Pluronic F127 has a central hydrophobic chain of polyoxypropylene and two outer 
hydrophilic chains of polyoxyethylene.9 The hydrophobic interactions between the 
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collapsed polyoxypropylene blocks result in the formation of micelles.10 There are 
several advantageous properties of Pluronic that make it suitable for antigen 
delivery including cellular uptake through endocytosis and high gene 
expression.9,4,3,11 There is also evidence that hydrophobic portions of synthetic 
polymers can initiate immune responses.12,13 
 Our research group has previously synthesized a family of cationic pentablock 
copolymers based on Pluronics for drug delivery.14 The pentablock copolymers, 
which are synthesized using Pluronic macroinitiators and atom transfer radical 
polymerization (ATRP) of the outer cationic blocks, offer several critical 
advantages for DNA-based vaccine delivery. The amine groups on the 
pentablock copolymer outerblocks can form nanoscale complexes with DNA 
spontaneously as a result of electrostatic interactions.15 Detailed studies with one 
of these pentablock copolymers with poly(2-diethylaminoethyl methacrylate) 
(PDEAEM) cationic blocks, have shown that the polymer micelles aggregate to 
form physical gels at high polymer concentrations. This enables the pentablock 
copolymers to serve as a unique multi-purpose platform to condense DNA, 
enable sustained gene delivery from the pentablock copolymer gels, and also 
provide combinational therapy of gene and drug co-delivery from the same 
platform.15,16 However, the effect of different cationic blocks on DNA 
complexation ability as well as cytotoxicity of the copolymers has not been 
investigated. Herein we synthesize four pentablock copolymers based on 
Pluronic with end blocks of PDEAEM, poly(2-dimethylaminoethyl methacrylate), 
poly(2-diisopropylaminoethyl methacrylate) or poly-(tert-butylaminoethyl 
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methacrylate) abbreviated PDMAEM, PDiPAEM and PtBAEM, respectively. 
These polymers with different cationic groups were then evaluated for suitability 
in a DNA-based vaccine formulation through DNA condensation and cellular 
cytotoxicity studies to select lead candidates. 
 To establish protective immunity, vaccines can enhance an innate immune 
response by activating antigen presenting cells (APCs).17 Dendritic cells are a 
critical type of APCs that are present in all body tissues.18 Immature dendritic 
cells can activate directly from pattern recognition receptors (PRRs) that 
recognize pathogen-associated molecular patterns (PAMPs) .18 Carbohydrates; 
such as mannose, have been shown to act as PAMPs which can target 
carbohydrate-recognition recognition receptors, specifically C-type lectin 
receptors abundantly expressed on dendritic cells.19–21 Ligation of C-type lectin 
receptors with mannose structures displayed by pathogen glycoproteins leads to 
internalization of pathogens for antigen loading of major histocompatibility 
molecules20,22. Therefore, nano-scale adjuvants with attached carbohydrates can 
act as virus-mimicking particles such as mannose containing HIV-1 and measles 
virus, and increase dendritic cell transfection efficiencies through receptor 
mediated endocytosis and presentation of processed antigen to T cells21. In this 
work, we demonstrate the successful functionalization of this family of pentablock 
copolymer vaccine candidates with D-mannose through an azide-alkyne Huisgen 
click reaction.23,24 Furthermore, gel electrophoresis studies show that the 
mannose functionalization of the copolymers does not affect the ability of the 
polymers to complex with DNA. A diagram showing the interaction of mannose 
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functionalized pentablock copolymer DNA polyplexes interacting with PRRs on a 
dendritic cell can be found in Scheme 1.   
4.3 Experimental Section 
4.3.1 Reagents 
 2-N,N-(diisopropylamino)ethyl methacrylate (DiPAEM), tert-butylaminoethyl 
methacrylate (tBAEM) and inhibitor removal columns were purchased from 
Scientific Polymer Products Inc., Ontario, NY. N,N-(dimethylamino)ethyl 
methacrylate (DMAEM), N,N-(diethylamino)ethyl methacrylate (DEAEM), Pluronic 
F127 (Mn = 12600, 70% PEO), and D-mannose were purchased from Sigma-
Aldrich, St. Louis, MO. Triphenyl bismuth was purchased from Strem Chemicals, 
Newburyport, MA. Slide-A-Lyzer® G2 Dialysis Cassettes (10KDa MW cut off) 
were purchased from Thermo Scientific, Rockford, IL. All other chemicals were 
purchased from Fisher Scientific, Pittsburgh, PA. The synthesis of N-propyl-
pyridynyl methanimine (NPPM) from 1-propylamine and 2-pyridinecarbaldehyde 
has been previously reported.25 
4.3.2 General Experimental  
 Air- and moisture-sensitive reactions were carried out in oven-dried or flame-
dried glassware, septum-capped under atmospheric pressure of argon. Commercially 
available compounds were used without further purification unless otherwise stated. 
The exact reaction conditions are given in the respective procedures. Air- and moisture-
sensitive liquids and solutions were transferred via syringe or stainless steel cannula. All 
saccharides and the Bi(V) reagent were pre-dried by azeotropic removal of water using 
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anhydrous toluene. Flash silica gel column chromatography was performed employing 
Silica Gel 60 Sorbent (40-63 m, 230-400 mesh). Thin-layer chromatography 
(analytical) was performed using glass plates pre-coated to a depth of 0.25 mm 
detected under UV light and by spraying the plates with a 0.02 M solution of resorcinol 
in 20% ethanolic H2SO4 solution followed by heating.  
4.3.3 Instrumentation  
 Proton (1H) NMR, carbon (13C) NMR, 1H-13C HSQC were recorded on a Bruker 
Avance  III 600 MHz (or Varian VXR 300 MHz), 125 MHz instrument respectively using 
the residual signals from chloroform (CDCl3), 7.26 ppm and 77.0 ppm as internal 
references for 1H and 13C chemical shifts () respectively. Electrospray ionization high-
resolution mass spectrometry (ESI-HRMS) was carried out on an Agilent 6540 QTOF. 
Optical rotations were measured at 20 °C using an automatic polarimeter AP300. 
Melting points were recorded in capillary tubes on a Digimelt SRS. IR spectroscopy was 
recorded by putting a thin film of the analyte on a salt plate on a Perkin-Elmer 
instrument. 
4.3.4 Preparation of Pluronic Macrointiator  
 Pluronic F127 (40.0 g, 3.20 mmol) was dissolved in tetrahydrofuran in a round-
bottom flask over an ice bath. Triethylamine (20.0 mL, 143 mol) and 2-
bromoisobutyryl bromide (3.00 mL, 24.2 mmol) were then added to the round-bottom 
flask. The reaction proceeded for 20 h up until the removal of solvent under reduced 
pressure and the precipitation of Pluronic macrointiator with n-heptane inside of a dry 
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ice bath. The characterization of Pluronic macrointiator by 1H NMR has been previously 
described.14 
4.3.5 Synthesis & Characterization of the Pentablock Copolymer Family   
 The PDEAEM, PDMAEM, PtBAEM and PDiPAEM pentablock copolymers 
were synthesized via ATRP with the Pluronic macrointiator. The macrointiator 
(10.0 g, 0.780 mmol) and copper(I) bromide (0.240 g, 1.67 mmol) were dissolved 
in toluene inside of an argon flushed single neck round bottom flask. The NPPM 
ligand (0.500 mL, 3.40 mmol) and respective monomer (2.50 mmol) were added 
and the reaction flask was degassed via three freeze-pump-thaw cycles. A small 
volume of inert gas was added and the reaction was stirred at 70 °C in an oil 
bath. After 20 h the reacted product was passed through a basic alumina column 
with a 1:1 dichloromethane:toluene solution. The eluate was concentrated under 
reduced pressure. The product was then precipitated using chilled n-heptane and 
left to dry in a vacuum oven maintained at 25 inches Hg vacuum (125 torr).  
4.3.6 DNA Gel Electrophoresis 
 To investigate the DNA condensation ability of polymers, the self-assembled 
pentablock copolymers were mixed with DNA in Hank's Balanced Salt Solution 
(HBSS) at different N/P ratios to form polyplexes. The polyplexes were briefly 
vortexed and incubated at room temperature for 20 min to ensure complexation. 
The samples were prepared in TriTrack sample buffer and a 15 µL volume was 
loaded onto a 0.70% agarose gel containing 0.1 g/ml ethidium bromide. These 
polyplexes were run on an agarose gel with a constant of 1 g of DNA per lane. 
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The gel was run in tris-acetate EDTA buffer at 75 V for approximately 2 h. All 
fluorescent images were captured on a UVP BioDoc-It® Imaging System with a 
1.3 megapixel camera. 
4.3.7 Cytoxicity Studies  
 The cytotoxicity of the different pentablock copolymers was tested using an in 
vitro CellTiter 96® Non-Radioactive Cell Proliferation Assay (Promega, Wisconsin, 
United States). EL4 C57BL/6 mice lymphoma cells were seeded on a 96 well plate with 
a density of 10,000 cells per well and incubated at 37 °C for 24 h in a humidified, 5% 
CO2 atmosphere. Pentablock copolymers dissolved in HBSS Buffer were added at 
concentrations calculated from an NP ratio of 20 for 0.2 µg and 0.6 µg of DNA and 
incubated with the cells at 37 °C for an additional 24 h. A 15 µL volume of the Promega 
tetrazolium salt reagent was added to each well, the 96 well plate was incubated for an 
additional 4 h and then a 100 µL volume of the Promega solubilization solution was 
added to each well. After an additional 1 h of incubation, absorbance values were 
recorded with a microplate reader at 570 nm wavelength and a subtracted 690 nm 
reference wavelength. Corrected absorbance values were found by subtracting an 
average absorbance value of the 100% lysed positive control cells. The cell viability 
numbers were calculated by dividing the corrected absorbance value by an average of 
the non-treated negative control cells. 
4.3.8 Functionalization of Pentablock Copolymer with Azide Linker 
 Pentablock copolymer (5.40 g) and sodium azide (0.243 g, 3.60 mmol) were 
dissolved in N,N-dimethylformamide and reacted at 50 °C for 24 h. The reacted 
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product was precipitated in chilled n-heptane, collected using a Büchner funnel 
and left in a vacuum oven to dry. 
4.3.9 Synthesis of Alkynyl Mannose Analogue 
4.3.9.1 n-Propyl-2,3,4,6-tetra-O-acetyl-1-thio--d-mannopyranoside (2)  
 A 0.500 M solution of peracetylated donor 126 (2.00 g, 5.77 mmol, 1.0 equiv.) 
and propanethiol (PrSH, 0.571 g, 7.50 mmol, 1.3 equiv.) were stirred for 0.5 h in 
anhydrous dichloromethane at 0 °C. Then, boron trifluoride dietherate (BF3.OEt2, 1.23 
g, 8.65 mmol, 1.5 equiv.) was added drop wise at 0 °C to the reaction mixture and then 
the reaction was left to stir at ambient temperature for 16 h. The reaction was quenched 
with excess triethylamine, diluted with CH2Cl2, filtered, and washed sequentially with 2 
M aqueous HCl, saturated aqueous NaHCO3, and water. The organic layer was dried 
over MgSO4 and concentrated under reduced pressure at 40 °C; the resulting residue 
was purified by silica gel column chromatography with hexane:ethyl acetate (4:1) to 
yield 2 as a white solid (1.95 g, 4.78 mmol, 83%); Rf 0.48 (hexanes:ethyl acetate 3:1); 
[]D + 73.3 cm3 g-1dm-1 (c 0.012 g cm-3, CHCl3; 1H NMR (600 MHz, [D1] CDCl3, 25 
°C, TMS)  = 5.32 (dd, J=3.1, 1.6, 1H; H-3), 5.28 (m, 1H; H-2), 5.25 (d, J=3.1, 1H; H-
1), 5.23 (m, 1H; H-4), 4.37 (ddd, J=9.3, 5.4, 2.3, 1H; H-5), 4.28 (dd, J=12.2, 5.5, 1H; H-
6a), 4.07 (dd, J=12.3, 2.4, 1H; H-6b), 2.66 – 2.47 (m, 2H; SCH2CH2CH3), 2.15 – 1.94 
(m, 12H; 4×CH3C=O), 1.69 – 1.57 (m, 2H; SCH2CH2CH3 ), 0.97 (t, J=7.3, 3H; 
SCH2CH2CH3). 13C NMR (151 MHz, [D1] CDCl3, 25 °C, TMS)  = 170.56, 169.96, 
169.75, 169.72 (4C; C=O), 82.64 (1C; C-1), 71.21, 69.46, 68.91, 66.37 (4C; C-2,3,4,5) 
62.45 (1C; C-6), 33.48 (1C; SCH2CH2CH3), 22.80 (1C; SCH2CH2CH3), 20.92, 20.70, 
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20.69, 20.62 (4C; 4×CH3C=O), 13.35 (1C; SCH2CH2CH3), HRMS (ESI-QTOF) m/z 
calc. for C17H26O9SNa+  429.119  found  429.126. 
4.3.9.2 2-Propynyl-2,3,4,6-tetra-O-acetyl-1-O--d-mannopyranoside (3) 
 A 0.50 M solution of thioglycoside donor 2 (0.250 g, 0.615 mmol, 1.0 equiv.) and 
propargyl alcohol (0.035 g, 0.615 mmol, 1.0 equiv.) were stirred together in anhydrous 
dichloromethane (CH2Cl2) for 0.5 h in a flask filled with Ar at ambient temperature. A 
solution of Ph3Bi(OTf)227 (0.317 g, 0.430 mmol, 0.700 equiv.) in anhydrous CH2Cl2 was 
added and the reaction was stirred at ambient temperature for 4 h (till the consumption 
of donor was seen by TLC). The reaction was then quenched by triethylamine, filtered 
through a Celite pad, and concentrated under reduced pressure; the resulting residue 
was purified by silica gel column chromatography with hexane:ethyl acetate (3:1)to give 
a pale white solid 3 (0.188 g, 0.486 mmol, 79%). The 1H NMR, 13C NMR, HRMS 
matched with data in the literature.28 
1H NMR (600 MHz, [D1] CDCl3, 25 °C, TMS)  [5.35 (dd, J = 10.0, 3.4 Hz), 5.31 
(d, J = 9.8 Hz), 5.29 – 5.27 (m) (3H; H-2,3,4)], 5.03 (d, J = 1.8 Hz, 1H; H-1), 4.31 
– 4.28 (m, 1H, H-6a), 4.28 (d, J = 2.3 Hz, 2H, CH2CCH), 4.11 (dd, J = 12.3, 2.5 
Hz, 1H, H-6b), 4.02 (ddd, J = 9.7, 5.2, 2.4 Hz, 1H, H-5), 2.47 (t, J = 2.4 Hz, 1H, 
CH2CCH), 2.17 (s, 3H), 2.11 (s, 3H), 2.04 (s, 3H), 1.99 (s, 3H) (4×CH3C=O). 
13C NMR (151 MHz, [D1] CDCl3, 25 °C, TMS)  96.23 (1C; C-1), 77.92, 75.62 
(2C, CH2CCH) , 69.33, 68.97, 68.91, 66.00 (4C; C-2,3,4,5), 62.30 (1C; C-6), 
54.94 (1C; CH2CCH), 20.85, 20.73, 20.68, 20.64 (4C; 4×CH3C=O). 
HRMS (ESI-QTOF) m/z calc. for C17H22O10Na+ 409.110 found 409.111. 
79 
 
4.3.9.3 2-Proynyl-1-O- -d -mannose 
 To a solution of 3a (0.188 g, 0.486 mmol) in 10.0 mL anhydrous methanol 
(MeOH), 0.2 mL of 0.5 N sodium methoxide (freshly prepared by dissolving 
sodium in anhydrous MeOH) was added. The reaction mixture was stirred at 
ambient temperature for 1 h, neutralized with Dowex 50WX8 (H+) cation 
exchange resin and filtered. The methanol was removed under reduced pressure 
and trace methanol or water was removed by co-evaporation with toluene (3 x 5 
mL) to give the desired product 4 as pale yellow solid (0.098 g, 0.447 mmol, 
92%), which was directly used in the click reaction.  
4.3.10 General Procedure for Azide-Alkyne Huisgen Reaction 
 To a solution of the pentablock copolymer (1.00 equiv.) and 4 (10 equiv.) in H2O, 
aqueous solutions of CuSO4•5H2O (0.20 equiv.) and L-ascorbic acid (0.40 equiv.) were 
sequentially added. The mixture was stirred at 35 °C for 24 h. The solvent was removed 
under reduced pressure and residual mixture was dried under vacuum overnight. 
4.3.11 Purification of Mannose Functionalized Pentablock Copolymers/Dialysis 
 The residue after the click reaction was dissolved in minimum amount (<3.0 
mL) of solvent (33% ethanol in water, except for PDiPAEM in which case 66% 
ethanol/water was used). The solution was then injected into a Slide-A-Lyzer® 
dialysis cassette (10KDa MW cutoff), and left for stirring overnight for 20 h in 
nanopure water. The leftover solvent inside the cassette was then evaporated 
under reduced pressure and the dialyzed sample was kept under vacuum 
overnight for complete dryness.  
80 
 
4.3.12 Phenol Sulfuric Acid Assay 
 The sugar attached pentablock copolymers were dissolved in nanopure water at 
a concentration of 1 mg/mL and 100 µL volume per well was added to a 96 well plate. A 
150 µL volume of stock sulfuric acid was added to each well following a 30 µL volume of 
5% phenol. The 96 well plate was heated for 30 min at 90 °C and the absorbance was 
read in a microplate reader at the 490 nm wavelength. 
4.3.13 Statistical Analysis 
 All error bars represent 95% confidence intervals for the mean. Differences 
between groups were analyzed with one-way analysis of variance (ANOVA) followed by 
Tukey’s multiple comparison test. The denoted statistical significance indicates a p-
value  0.05. 
4.4 Results & Discussion 
4.4.1 The Synthesis & Characterization of the Family of Pentablock Copolymers  
 A family of pentablock copolymers (PDEAEM, PDMAEM, PDiPAEM and 
PtBAEM) previously developed by our group as injectable drug delivery devices 
exhibit remarkable reversible gelation around physiological temperatures and 
vary in their pH-dependent micellization behavior.14,2,4,29 These were synthesized 
using a Pluronic macronitiator triblock and different amine containing cationic 
blocks utilizing ATRP. To ensure biocompatibility, the molar mass was 
maintained below the 20 kDa cut off for renal excretion by the kidneys.30 Scheme 
2 is a schematic of the ATRP synthesis reaction for the four different pentablock 
copolymers. The pentablock copolymers were characterized by 1H NMR and the 
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number average molar mass (Mn) was calculated from the integral per proton 
ratio using the known chain length of the central triblock pluronic. The 1H NMR 
spectra and a table of molecular weights can be found in Figure 1 and Table 1 
respectively. Previous studies by our research group with the PDEAEM 
pentablock copolymer have demonstrated that these block copolymers form 
charged spherical micelles at low pHs with a hydrodynamic radius of 
approximately 10 nm that increase in size and transition into cylindrical micelles 
above a critical pH.31,14 These polymers are potential candidates for injectable 
gene delivery and as such were then tested for compatibility as DNA delivery 
platforms. 
4.4.2 DNA Condensation & Cytotoxicity Studies  
 Agarose gel electrophoresis was used to determine the minimum concentration 
of pentablock copolymer required to form a polyplex based on the ratio of 
charged nitrogen atoms in the pentablock copolymer’s tertiary amine groups and 
the negatively charged phosphate groups in the DNA backbone denoted as the 
N/P ratio. Figure 2 shows fluorescent images of agarose gels containing the four 
different pentablock copolymers at various N/P ratios. In wells where the DNA did 
not migrate, the quantity of pentablock copolymer was large enough to neutralize 
the negative DNA charge, indicating the formation of polymer-DNA polyplexes. 
PDEAEM, PDMAEM and PtBAEM complexed with DNA at minimum N/P ratios of 
3, 1 and 1 respectively. The PDiPAEM pentablock copolymer with the 
hydrophobic isopropyl groups was insoluble in water. This pentablock copolymer 
was unable to complex with DNA at N/P ratios less than 10, which may be 
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attributed to the necessary sonication that was required to dissolve this block 
copolymer. A lower N/P ratio is desirable when designing a DNA-based vaccine 
formulation due to the reduction of the necessary amounts of the cytotoxic 
cationic groups on the polymers.  
 The primary obstacle that researchers developing adjuvants must overcome is 
toxicity, since cationic groups that can complex with DNA can be cytotoxic, which 
is why the cytotoxicity of the different polymers was investigated.18,32 The 
cytotoxicity of the pentablock copolymers was determined using a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Four 
pentablock copolymers of similar molecular weights at the same N/P ratio were 
tested at low and high polymer concentration ranges used typically for DNA 
transfection studies.29,33,30,34 Unfortunately, it was observed that the cells treated 
with the PtBAEM pentablock copolymer did not survive at high or even low 
concentration ranges. While the other three polymers showed low cytotoxicity, 
the differences between the PDEAEM, PDMAEM and PDiPAEM pentablock 
copolymers were statistically significant at the higher polymer concentration 
range (Figure 3). The required sonication of the PDiPAEM pentablock copolymer 
may have contributed to the low cytotoxicity of this block copolymer. 
4.4.3 Functionalization of Pentablock Copolymers with d-mannose via Azide-
Alkyne Huisgen Cycloaddition  
 The D-mannose was attached to the pentablock copolymer via Huisgen 
cycloaddition by functionalizing the polymer with an azide group and the 
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mannose with an alkyne linker. As previously reported,35 bromo-terminated 
polyacrylates can be easily substituted by the nucleophilic azide group hence the 
halogen end groups of the pentablock copolymers were replaced by azide 
(Scheme 3). A distinct peak present between 2100 and 2300 cm-1 represents the 
azide functionalization of the pentablock copolymers (Figure 4) which was 
previously absent in the non-azide functionalized polymers. 
 We recently developed27 a simple, efficient thioglycoside activation protocol 
utilizing bismuth(V) chemistry36,37 with a wide variety of carbohydrates containing 
various functional groups. This method, unlike most other current methods,38,39 
can be performed at ambient temperatures without the use of any additives/co-
promoters. Moreover, unlike many thioglycoside activation methods that rely on 
promoter interactions with the soft sulfur that preclude the facile use of alkenes 
anywhere in the glycosyl donor or acceptor, this bismuth-mediated method was 
shown to work effectively in the presence of alkenyl groups.  In order to install the 
alkyne linker onto the carbohydrate, we further investigated the application of this 
method in the presence of terminal alkynyl systems, which like alkenes are also 
prone to addition by–products. The synthesis of the desired mannose analogue 
(Scheme 4) containing the alkyne moiety started with peracetylation of 
commercially available D-mannose, which was then converted to a new thiopropyl 
mannoside donor 2. The donor 2 was then activated with propargyl alcohol to 
give the alkyne linked mannose 3 in 79% yield, without any interference with the 
alkyne moiety. Finally, 3 was deacetylated to give the final alkynyl mannose 4 in 
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overall 50% yield in 5 steps. 1D and 2D NMR spectra of the mannose derivatives 
are available in the supporting information.  
After the azide and alkyne functionalization of the polymer and mannose 
respectively, they were coupled together via a Huisgen azide-alkyne click 
reaction catalyzed by a mixture of CuSO4•5H2O and L-ascorbic acid (Scheme 5).  
4.4.4 Purification and Analysis of the Attachment of D-mannose to Pentablock 
Copolymers: IR Spectroscopy, and Phenol Sulfuric Acid Assay 
 The next crucial part was to characterize the attachment as well as quantify the 
amount of sugar attached to the polymer. Unfortunately, the initial studies using 
mass spectroscopy (specifically MALDI-TOF) and 15N labeled 1-D & 2-D NMR 
spectroscopy were not definitive. However, IR spectroscopy results showed the 
presence and absence of peaks, particularly a distinct azide peak (~2050-2300 
cm-1) (Figure 4) before/after reaction, but did not quantify the coupling. The 1H 
NMR spectra of the pentablock copolymers before and after attachment 
(Supporting Information) also shows new peaks in the region of 5-7 ppm, which 
are probably from the triazole ring protons and the mannose protons after the 
click reaction. However, since these protons are too small in number compared to 
the copolymer protons, they are difficult to accurately integrate to quantify the 
attachment. 
 In order to accurately quantify the amount of mannose attached to the polymer, 
a phenol sulfuric acid assay was carried out by dissolving the pentablock 
copolymers in water and reacting the carbohydrates with phenol in the presence 
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of sulfuric acid (Figure 5). Prior to these assays, the mannose functionalized 
pentablock copolymers were purified from the unreacted sugar/excess reagents 
by utilizing dialysis membrane cassettes to rule out detection of unattached 
sugar. The separation of the excess sugar as well as excellent coupling of the 
two were clearly evident in the phenol sulfuric acid assay values from before and 
after dialysis samples. The PDiPAEM pentablock copolymer was slightly soluble 
in water with vortexing but continuously precipitated out of solution at relatively 
low concentrations. For this reason, sonication was used for the mannose 
functionalized PDiPAEM pentablock copolymer for all characterization assays. 
Overall, it was determined that the dialyzed pentablock copolymers had 
approximately two moles of mannose present per mole polymer indicating that 
the azide-alkyne click reaction produced near-complete conversion.  
4.4.5 DNA Condensation of Mannose Functionalized Block Copolymers 
 We envisioned that the addition of the mannose to the pentablock copolymers 
should not hamper their ability to condense DNA since this ability comes from the 
tertiary amine groups present in the outerblocks. Nevertheless, we performed gel 
electrophoresis on the mannose attached copolymers to test this hypothesis. The 
minimum N/P ratios for DNA complexation did not change for any of the four 
pentablock copolymers after the azide-alkyne Huisgen reaction indicating that the 
attached mannose did not impact the capability of the block copolymers to 
condense DNA (Figure 6).  
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4.5 Further Discussion 
 Based on all the above studies, the PDEAEM and PDMAEM pentablock 
copolymers appear to be the optimal subunit vaccine candidates due to their low 
cytotoxicity and relatively small N/P ratios required for DNA condensation. The 
PDiPAEM pentablock copolymer was insoluble in water, requiring the use of 
slightly cytotoxic DMSO solvent or use of sonication, and did not complex with 
the DNA plasmid at relatively low N/P ratios. Although the PtBAEM pentablock 
copolymer complexed with DNA at a low N/P ratios, it proved to be highly 
cytotoxic.  
 C-type lectin receptors expressed by dendritic cells and macrophages 
internalize pathogens after binding carbohydrate structures on their surface40. 
Recently, a carbohydrate-functionalized polymer synthesized by Charville et al.  
demonstrated that copolymers containing a higher degree of mannose 
functionalization were more prone to binding lectin receptors.41  Our method 
which includes the functionalization with mannose alkyne linker synthesized by 
bismuth(V)-mediated activation of a thioglycoside has yielded pentablock 
copolymers with hydrophobic polyoxyproplyene blocks that self-assemble into 
micelles. These pentablock copolymers are capable of condensing DNA for gene 
delivery through tertiary amine groups in the outer blocks.  
 Carbohydrate functionalized particles have been shown to enhance the 
expression of MHC II, costimulatory molecules and c-type lectin receptors by 
dendritic cells.19 The high carbohydrate- functionalization of the pentablock 
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copolymers may provide benefits when compared to other reported functionalized 
vaccine platforms, which typically focus on the decoration of particle surfaces.42–
49
 The continued presence of sugars attached to polymer may provide increased 
and longer-lasting activation of immune cells as compared to a sugar-decorated 
particle, which may erode and slough off the sugars quickly. 
4.6 Conclusions 
 Herein we report the synthesis of a family of pentablock copolymers based on 
Pluronic macrointiators. These four polymers were then tested as potential DNA 
vaccine candidates using cytotoxicity assays and their DNA complexation 
abilities. The block copolymers PDEAEM and PDMAEM were chosen as the lead 
candidates for a DNA vaccine delivery platform due to their ability to condense 
DNA at low N/P ratios and with relatively low cytotoxicity. All four of the block 
copolymers were successfully functionalized with mannose by a high-yielding 
azide-alkyne Huisgen reaction. In addition, the cheap, non-toxic Bi(V)-mediated 
thioglycoside activation method proved to be applicable to cases containing 
alkynes for the synthesis of alkynyl mannose in high yield. The addition of 
mannose to the polymer did not destroy the ability of the polymers to complex 
DNA and therefore these new sugar-modified materials have the potential to 
activate APCs. These promising virus-mimicking nanoparticles for DNA-based 
vaccine delivery will be evaluated in future studies for APC activation and 
immune response generation. 
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Figure 1. 1H NMR spectra of pentablock copolymers: (A) PDEAEM pentablock 
copolymer (B) PDMAEM pentablock copolymer (C) PDiPAEM pentablock copolymer (D) 
PtBAEM pentablock copolymer 
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Figure 2. Agarose gel electrophoresis of pentablock copolymer polyplexes at N/P ratios 
of 1, 3, 5 and 10 with a DNA only control (A) PDEAEM (B) PDMAEM (C) PDiPAEM (D) 
PtBAEM 
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Figure 3. The differences in cytotoxicity between the pentablock copolymers (A) A 
polymer concentration calculated from an N/P ratio of 20 for 0.2 µg of DNA per well. (B) 
A polymer concentration calculated from an N/P ratio of 20 for 0.6 µg of DNA per well. 
The data presented are 95% confidence intervals for the mean for four independent 
experiments and letters indicate statistical differences between groups where a p-value 
 0.05.  
 
 
Figure 4: IR spectrum comparison of (A) PDEAEM before and (B) after azide-alkyne 
Huisgen reaction with mannose analogue 4 
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Figure 5. Quantification of mannose functionalized pentablock copolymers. The 
data presented are 95% confidence intervals for the mean for four independent 
experiments 
 
 
Figure 6. Agarose gel electrophoresis of mannose functionalized pentablock copolymer 
polyplexes at N/P ratios of 1, 3, 5 and 10 with a DNA only control (A) PDEAEM 
pentablock copolymer (B) PDMAEM pentablock copolymer (C) PDiPAEM pentablock 
copolymer (D) PtBAEM pentablock copolymer 
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Scheme 1. Illustration of mannose functionalized pentablock copolymer condensing 
DNA and interacting with pattern recognition receptors (PRRs) on an antigen presenting 
cell.  
 
 
 
 
 
 
 
 
Scheme 2: ATRP synthesis of block copolymer family 
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Scheme 3: Azide functionalization of block copolymer family 
 
Scheme 4: Preparation of D-mannose with the alkyne linker 
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Scheme 5: Azide-alkyne Huisgen cycloaddition between D-mannose and the various 
pentablock copolymers 
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Tables 
 
Table 1. Average molecular weight (Mn) and chain length (n) calculated from 1H NMR 
spectra of pentablock copolymers. 
 
 
Pentablock 
Copolymer 
Mn            
g mol-1 
N              
chain length 
PDEAEM 15,500 7.5 
PDMAEM 14,300   4.1 
PDiPAEM 13,700 2.4 
PtBAEM 13,000 0.7 
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CHAPTER 5: EFFECTIVE POLYMER ADJUVANTS FOR 
SUSTAINED DELIVERY OF PROTEIN SUBUNIT VACCINES 
 
A paper submitted to Acta Biomaterialia 
 
5.1 Abstract  
  We have synthesized thermogelling cationic amphiphilic pentablock copolymers 
that have the potential to act as injectable vaccine carriers and adjuvants that can 
simultaneously provide sustained delivery and enhance the immunogenicity of released 
antigen. While these pentablock copolymers have shown efficacy in DNA delivery in 
past studies, the ability to deliver both DNA and protein for subunit vaccines using the 
same polymeric carrier, can provide greater flexibility and efficacy. We demonstrate the 
ability of these pentablock copolymers, and the parent triblock Pluronic copolymers to 
slowly release structurally intact and antigenically stable protein antigens in vitro, create 
an antigen depot through long-term injection-site persistence, and enhance the in vivo 
immune response to these antigens. We show release of the model protein antigen 
ovalbumin in vitro from the thermogelling block copolymers with the primary, secondary 
and tertiary structures of the released protein unchanged compared to the native 
protein, and its antigenicity preserved upon release. The block copolymers form a gel at 
physiological temperatures that serves as an antigenic depot and persists in vivo at the 
site of injection for over 50 days. The pentablock copolymers show a significant five-fold 
enhancement in the immune response compared to soluble protein alone, even 6 
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weeks after the administration, based on measurement of antibody titers. These results 
demonstrate the potential of these block copolymers hydrogels to persist for several 
weeks and sustain the release of antigen with minimal effects on protein stability and 
antigenicity; and their ability to be used simultaneously as a sustained delivery device 
as well as a subunit vaccine adjuvant platform. 
5.2 Introduction 
Much recent work in vaccine design has focused on the delivery of pathogenic 
subunits such as proteins or DNA in place of a live, attenuated or killed organism. Such 
subunit vaccines are typically safer than live or attenuated viruses, but need an adjuvant 
to boost the immune response[1]. Recently, synthetic polymeric adjuvants are being 
explored as they have the advantage of serving simultaneously as adjuvants as well as 
sustained delivery devices for release of the antigen, without some of the potential 
toxicity concerns associated with microorganism-derived adjuvants[1]. The need for the 
development of a vaccine delivery system where release kinetics can be controlled in 
vivo is implied by empirical evidence that suggests that sustained delivery may be a 
factor in adjuvanticity[2–5].  
Amphiphilic block copolymers that spontaneously gel at physiological 
temperatures have great potential as injectable sustained delivery systems[6]. The 
phase behavior of Pluronics that contain a central hydrophobic block of 
polyoxypropylene (POP), flanked by two hydrophilic blocks of polyoxyethylene (POE), 
and their responsiveness to changes in solution conditions have been widely studied[7–
9]. At high concentrations, Pluronics exhibit a thermoreversible gel phase at 
102 
 
physiological temperatures caused by the association of micelles[8]. We have 
synthesized pH-dependent pentablock copolymers based on Pluronics and 
poly(diethylaminoethylmethacrylate) (PDEAEM) blocks with tertiary amine groups in 
their outer cationic blocks, that retain the thermogelling characteristics of the 
poloxamers, while also providing pH as an additional tuning mechanism for controlling 
release[8]. The release rates from these gels can be controlled by changing the 
concentration of polymer or the surrounding pH. An increase in block copolymer 
concentration leads to a decrease in release rates[10]. The pentablock copolymers also 
exhibit slower release rates than the Pluronics and the release rate can be potentially 
controlled by varying the length of the cationic blocks[11]. This may have implications 
for vaccine design by providing a controlled release system for the antigen.  
In addition to serving as a delivery vector, these block copolymer hydrogels can 
serve as vaccine adjuvants by enhancing the immunogenicity of the antigen. A 
suspected mechanism of adjuvanticity of conventional adjuvants, such as incomplete 
Freund adjuvant, is the depot effect, where antigen release is sustained over a period of 
several days or weeks from the injection site[12]. A known property of these block 
copolymer hydrogels is their ability to slowly release their payloads through the 
disassociation of aggregated micelles. Furthermore, hydrophobic portions of polymers, 
such as the central hydrophobic POP blocks in block copolymers, are thought to interact 
with pattern recognition receptors that comprise innate immunity[13]. We have also 
successfully functionalized the bromo-terminated polyacrylate end blocks with mannose 
which has the potential to increase activation of antigen presenting cells[14]. In this 
study we use the model antigen ovalbumin (OVA), which is one of the most widely used 
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protein for vaccine studies. Benefits of using the ovalbumin model include well 
established immunological assays, cross platform comparison to other antigen delivery 
systems, and a relatively low cost compared to use of more medically relevant 
proteins[15–17]. To investigate this adjuvant effect of block copolymers, we have 
investigated the ability of the block copolymers to enhance antigenicity by measuring 
the humoral immune response of mice immunized against OVA.  
The development of polymers that offer sustained released has added additional 
challenges such as the risk of degradation of the payload, delivered days to months 
after administration from the prolonged exposure to the polymeric delivery vector[18]. 
The cationic blocks of the pentablock copolymers form complexes with DNA and enable 
efficient DNA delivery[19–21]. The same polymers can also be used for simultaneous 
delivery of proteins to form multifunctional delivery platforms for sub-unit vaccines. 
However, these proteins are highly intricate structures that must maintain integrity in 
order to properly function[18]. Proteins are exposed to multiple stresses during the 
entrapment or encapsulation process including elevated temperatures, vigorous 
agitation and exposure to organic solvents or acidic environments[18,22]. In addition to 
manufacturing methods, proteins are also susceptible to degradation after 
administration caused by changes in the microenvironments from polymer degradation 
products[18]. Taken together, these data suggests that antigen stability is an important 
consideration when constructing a subunit vaccine.  
Therefore, the work here investigates in detail the preservation of structure and 
function of protein released in vitro from the pentablock copolymer vaccine platform. 
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This allows us to build on our earlier work in using these pentablock copolymers for 
DNA delivery[21,23] and to develop a unique injectable polymer carrier that can be used 
potentially simultaneously for both DNA and protein delivery for subunit vaccines, for 
maximum efficacy. Protein was released from the thermogelling block copolymers 
through polyethylene glycol diacrylate barrier gels to mimic an in vivo tissue 
environment and protein primary, secondary and tertiary structures were examined 
using SDS-Page, circular dichroism and ultraviolet-visible spectroscopy, respectively. 
The antigenicity of the released protein was determined using an enzyme-linked 
immunosorbent assay to measure the ability of released ovalbumin to be recognized by 
a monoclonal antibody. To investigate the persistence of these formulations in vivo, 
mice were administered fluorescently labeled block copolymer hydrogels and 
persistence was analyzed using a live animal imaging system. Taken together, the 
following studies investigate the ability of the pentablock copolymer system to serve as 
a new ideal vaccine adjuvant by providing sustained delivery of the protein antigen 
release with preservation of its structure and function, its ability to persist in vivo, and to 
enhance the immune response to the antigen.  
5.3 Experimental Section 
5.3.1 Materials 
 N,N-(diethyl amino)ethyl methacrylate (DEAEM), polyvinylpyrrolidone (Mn = 
40000), Pluronic F127 (Mn = 12600, 70% PEO), ovalbumin protein (44 kDa) and 
antibodies were purchased from Sigma-Aldrich (St. Louis, MO). Slide-A-Lyzer™ dialysis 
cassettes and Micro BCA protein assay kits were purchased from Pierces 
Biotechnology (Rockford, IL). Poly(ethylene glycol) diacrylate (Mw = 4000) was 
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purchased from Polysciences Inc. (Warrington, PA). Pluronic F127 and Irgacure 2959 
photointiator were purchased from BASF (Florham Park, NJ). Alexa Fluor® 647 Alkyne 
was obtained from Life Technologies (Grand Island, NY). All other materials including 
Spin-X UF™ Concentrators and 6-well plate Transwell® Microplate Membrane Inserts 
were purchased from Fisher Scientific (Pittsburgh, PA). The synthesis of N-propyl-
pyridynyl methanimine (NPPM) from 1-propylamine and 2-pyridinecarbaldehyde and 
cuprous oxide nanoparticles from copper acetate, sodium borohydride and 
polyvinylpyrrolidone has been previously described[24–26]. 
5.3.2 Pentablock Copolymer Synthesis  
 The synthesis of PDEAEM pentablock copolymers with cuprous oxide 
nanoparticles has been previously reported[25]. Briefly, a solution of cuprous oxide 
nanoparticles (0.24 g, 1.68 mmol) in 50 mL of toluene was briefly sonicated in a round-
bottom flask. Pluronic macrointiator (10 g, 0.78 mmol) was added before a rubber 
stopped was securely fastened with a cable tie. The reaction flask was degassed by 
vacuum-argon three times to remove air. The NPPM ligand [0.5 mL, 3.40 mmol] and 
DEAEM monomer [4 mL, 2.53 mmol] were injected into the reaction flask and several 
freeze-pump-thaw cycles with liquid nitrogen were used to further remove oxygen. The 
reaction was carried out inside of a water bath at 70°C and 300 RPM (PMC 720 Series 
DataPlate digital hot plate). After 20 hours the reacted product was passed through a 
column of basic alumina with a 1:1 dichloromethane:toluene solution, the eluate was 
evaporated with a rotary evaporator and the polymer precipitated in chilled n-heptane. 
The precipitant was collected using a Büchner funnel and left in a vacuum oven to dry.  
106 
 
5.3.3 Poly(ethylene Glycol) Diacrylate Barrier Gel Formation 
To form the poly(ethylene glycol) diacrylate (PEG-DA) barrier gels, a mold was created 
using a 24-well plate and glass test tubes. Glass test tubes were cut and glued onto the 
lid of the 24-well plate so that the round bottom protruded into the well when the plate 
was assembled. Inside each well a solution of 100 mg of polyethylene glycol diacrylate, 
55.56 mg of Pluronic F127, 266.67 µL of water and 133.33 µL of a 0.2 wt.% 
photoinitator in water was added. The mold was then photo-crosslinked using a UV 
wand of 50 MW/cm2 for 5 minutes. The barrier gels were scrapped out of the well plate 
using a spatula and placed in 50 mL of deionized to allow the formation of pores by the 
dissolution of Pluronic in water. The water was changed every day for 3 days at 4 °C 
until ready for use.  
5.3.4 Protein Release Kinetics from Block Copolymer Gels 
 Block copolymer solutions containing 20, 25 and 30 wt.% Pluronic F127 or 20 
wt.% PDEAEM pentablock copolymer and 5 mg/mL of OVA protein were chilled on ice 
at concentrations exceeding 20 wt.% and PEG-DA barrier gels were pre-warmed in a 
water bath. A 6-well plate with 1.5 mL of deionized water in each well was equipped 
with Transwell® inserts. The pre-warmed gels were placed on the Transwell® inserts 
and the vector solutions containing protein were injected on the concave top surface of 
the PEG-DA hydrogels. This process allowed the gelation of the vector solution to occur 
due to temperature change. The plates were placed inside of a 37 °C shaker rotating at 
100 RPM to mimic physiological conditions. Samples were taken after the first 4 hours 
and every 24 hours for one week by replacing the 1.5 mL of deionized water at the 
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bottom of the well plates. Protein concentration was measured with a Micro BCA 
analysis at an absorbance of 570 nm. 
5.3.5 OVA Incubation with Block Copolymers 
 OVA protein was incubated in block copolymer solutions containing 20, 25 and 
30 wt.% Pluronic F127 or 20 wt.% PDEAEM pentablock copolymer in a volume of 1 mL 
of nanopure water. The concentration of OVA protein in the stability studies, 100 
mg/mL, was higher than that used in the release experiments due to the number of 
assays performed and to compensate for losses during protein purification. The stability 
samples were incubated inside of a 37 °C shaker at 100 RPM to mimic physiological 
conditions. After one or seven days of incubation, the protein was separated from the 
polymer using Slide-A-Lyzer™ dialysis cassettes (20,000 MWCO Membrane) followed 
by Spin-X UF™ Concentrators (30,000 MWCO Membrane). Protein concentration was 
measured using a Micro BCA analysis at an absorbance of 570 nm. 
5.3.6 SDS-PAGE 
 Equal quantities of released protein, at a concentration of 100 µg/mL, were mixed 
with 2x Laemmli sample buffer. -mercaptoethanol was added to bring its concentration 
to 5% and the samples were heated at 95 °C for 5 minutes and cooled to room 
temperature. Next, they were loaded onto 4–20% Tris–HCl pre-cast gels along with a 
prestained molecular weight ladder and run at 150 V for approximately 90 minutes. The 
gels were then removed and placed in fixative solution (40% ethanol, 10% acetic acid) 
at 4 °C for 3 hours. The gels were then incubated in a 10% volumetric solution of 
flamingo gel stain overnight at 4 °C. A GE Healthcare Typhoon 8600 scanner 
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(Piscataway, NJ) in combination with ImageQuantTL software was used to obtain 
fluorescent images of the gels. 
5.3.7 Circular Dichroism 
 Far UV circular dichroism (CD) was performed to measure the changes in protein 
secondary structure after incubation with polymer. Measurements were collected on a 
Jasco J-710 (Easton,MD) instrument between the range of 190 to 250 nm at a protein 
concentrations of 100 µg/mL in water. Samples were ran in a 1 cm quartz cell. A total of 
3 measurements were averaged for each spectra.  
5.3.8 Ultraviolet-Visible (UV-vis) Spectroscopy 
 Tertiary structure was analyzed at protein concentrations of 5 mg/mL in 
deionized water using a Molecular Devices SpectraMax M3 Microplate Reader 
(Sunnyvale, CA). The emission spectra were collected in the range of 200 nm to 400 
nm. The protein spectra were corrected by subtracting the background of a blank 
solution.  
5.3.9 Enzyme-linked Immunosorbent Assay (ELISA) 
 The antigenicity of the ovalbumin incubated with the block copolymers and the 
serum antibody titer of immunized animals were analyzed using ELISA. For both 
experiments, samples containing protein at a concentration of 1 µg/mL were added into 
each well of a high protein binding Costar® plate and incubated overnight at 4 °C. 
Plates were washed three times with phosphate buffered saline containing 0.05% 
Tween 20 (PBST) and blocked with a 2.5% milk solution in PBST. After 2 hours of 
blocking at room temperature and three wash cycles with PBST, monoclonal Anti-OVA 
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antibody diluted 1:10,000 in PBST was added to each well and incubated overnight at 4 
°C for the antigenicity experiments. For the determination of anti-ovalbumin antibody 
titer, mouse sera was added at a dilution of 1:200 to PBST, the sera was then diluted 
serially, 1 to 3 for a total of 12 dilutions. All sera samples were tested in duplicate. After 
three wash cycles with PBST, an alkaline phosphatase-conjugated anti-mouse IgG 
secondary antibody diluted 1:40,000 was added and incubated in each well for 2 hours. 
The plates were washed for three additional cycles with PBST. Alkaline phosphatase 
substrate was prepared in sodium carbonate buffer (pH 9.3) containing 1 mg/mL 
phosphatase substrate and a 100 µL volume was added to each well. The optical 
density was measured at 405 nm using a plate reader after 30 minutes incubation. 
Antibody titer is herein defined as the dilution at which the optical density was greater 
than twice that of the average of the saline controls. 
5.3.10 Pluronic F127 Functionalization with Alexa Fluor 647 
 A Huisgen azide-alkyne click reaction was utilized to conjugate Alexa Fluor® 647 
alkyne to Pluronic F127. For the initial azide functionalization of the block copolymer, 
Pluronic macrointiator (5.40 g, 0.42 mmol) and sodium azide (0.243 g, 3.60 mmol) were 
dissolved in N,N-dimethylformamide and reacted at 50 °C for 24 h. The reacted product 
was precipitated in chilled n-heptane, collected using a Büchner funnel and left in a 
vacuum oven to dry. IR spectroscopy results showed the addition of distinct azide peak 
(~2050-2300 cm-1) present after the azide functionalization of the Pluronic macrointiator. 
An excess of azide functionalized Pluronic was then reacted with AF647 alkyne (0.500 
mg), cupric sulfate (1 mg, 4.01 µmol) and L-ascorbic acid (2 mg, 11.4 µmol) in water. 
The mixture was stirred at 35 °C for 24 h. The reacted solution was then injected into a 
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Slide-A-Lyzer® dialysis cassette (10KDa MW cutoff) and left for stirring overnight for 20 
h in nanopure water. The solvent was then removed under reduced pressure and the 
dialyzed sample was dried overnight in a vacuum oven. 
5.3.11 Mice 
 Five to seven week old female albino C57BL/6 mice purchased from Jackson 
Laboratories, Bar Harbor, Maine, were used for these experiments. The Institutional 
Animal Care and Use Committee (IACUC) at Iowa State University approved all 
protocols involving animals. 
5.3.12 In Vivo Polymer Persistence 
 To study in vivo persistence, the AF647 functionalized Pluronic F127 was 
administered to albino C57BL/6 mice and images were taken with an in vivo live animal 
imager. A 150 µL volume of a 20 wt.% Pluronic F127 hydrogel containing 1 mg/mL of 
AF647 block copolymer was subcutaneously administered into the flank of four mice. A 
control group of mice were administered saline alone. The mice were anesthetized with 
isoflurane inhalation and scanned with a Kodak In Vivo Imaging System FX PRO 
(Kodak BioMax, Rochester, NY) at multiple time points. A white light image with a 2 
second exposure time was taken followed by a fluorescent image with a 10 second 
exposure time at an excitation of 650 nm and a 700 nm emission filter. Mean 
fluorescence intensity (MFI) was assessed from a region of interest using the ImageJ 
image analysis software (National Institutes of Health, Bethesda, MD). The fluorescent 
images were then inverted and the false-color look-up table, “jet”, was applied. The 
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fluorescent image was then overlaid on the white light image to create the composite 
images.  
5.3.13 Antibody Titer Experiment 
 The ability of the block copolymers to enhance the humoral immune response 
was studied by immunizing mice against OVA with block copolymer solutions containing 
either Pluronic F127 or PDEAEM pentablock copolymer. A total of 4 mice per group 
were subcutaneously immunized with 100 µg of OVA in the specified block copolymer 
formulations, containing 25 mg of polymer, at a 150 µ L volume at the flank. The 
hydrogel formulation was kept on ice until administration, where the mice’s physiological 
temperature caused the formation of a hydrogel. Serum samples were collected via 
saphenous vein puncture at 2, 4 and 6 weeks and antibody titers were measured using 
an enzyme-linked immunosorbent assay as described above. 
5.3.14 Statistics 
 All error bars represent standard error of the mean. Differences between groups 
were analyzed with one-way analysis of variance (ANOVA) followed by Tukey’s post 
hoc test. The denoted statistical significance indicates a p-value  0.05. 
5.4 Results 
 Our research group has previously demonstrated a novel method for synthesis of 
the pentablock copolymer family using cuprous oxide nanoparticles, as an easily 
removable catalyst[25]. This method reduces the cytotoxicity of the polymer, providing 
an advantage for potential in vivo biomedical applications. Additionally, we have shown 
the ability to easily functionalize the bromo-terminated polyacrylate end blocks with 
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mannose, which has the potential to increase activation of immune cells, such as 
dendritic cells and macrophages through increased pattern recognition receptor 
recognition[14]. Based on these promising results, we now focus on evaluating the 
potential of the pentablock copolymer platform as a delivery system and adjuvant for 
subunit vaccine formulations based on proteins. It has previously been shown that the 
cationic end blocks of the pentablock copolymer can complex with DNA for nuclear 
delivery[20,21,27]. Here, we investigate the potential for the delivery of protein in 
subunit vaccine formulations, possibly leading to gene and protein co-delivery with the 
polymer.  
In order to optimize a protein subunit vaccine formulation and investigate the 
mechanisms of action, ovalbumin was chosen as a model protein. There are a number 
of in vitro and in vivo vaccine models focused on this protein, including fluorescently 
labeled protein, OVA-specific tetramers, and a mouse model with OVA specific T 
cells[28–30]. Future work will focus on transitioning to medically relevant proteins such 
as the hemagglutinin protein of the highly pathogenic avian influenza H5N1 virus. This 
work focuses on demonstrating the ability of a subunit vaccine using the pentablock 
copolymer to deliver intact, functional protein to immune cells to prevent the loss of any 
protective epitopes, and to demonstrate the adjuvanticity of these polymers through an 
enhanced immune response to the antigen. 
5.4.1 Pentablock Copolymer Synthesis 
Poly(2-dimethylaminoethyl methacrylate) (PDEAEM) pentablock copolymer was 
synthesized from the Pluronic macrointiator triblock through atom transfer radical 
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polymerization (ATRP). The polymerization reaction was catalyzed using cuprous oxide 
nanoparticles as previously reported[25]. The pentablock copolymer was characterized 
by 1H NMR (Figure 1) and the average molar mass was found to be approximately 
16,000 g/mol which was calculated using the integral per proton ratio and the known 
chain length of the central triblock. The overall molecular weight of the polymer was 
kept in that range to allow for renal excretion[20]. 
5.4.2 Barrier Gel Formation and Protein Release Studies 
Poly (ethylene glycol) diacrylate (PEG-DA) hydrogels can and have been used to 
act as in vitro mimics of the extracellular matrix[31–33]. PEG-DA exposed to UV light 
experiences rapid polymerization in the presence of photoinitiators that generate 
radicals[34,35]. The addition of water soluble Pluronic F127 prior to crosslinking leads to 
the formation of porous barrier gels after dissolution in water[23]. These barrier gels 
were used to mimic an in vivo environment, in order to test the controlled release of the 
block copolymer vaccine formulations using the model protein ovalbumin.  
Vector formulations containing 20, 25 and 30 wt.% Pluronic F127 or 20 wt.% 
PDEAEM pentablock copolymer were injected onto to the barrier gels, and maintained 
at 37°C in an incubated shaker, causing the vector solutions to transition into the gel 
phase (Figure 2). Release samples were taken up to 7 days. This experiment 
demonstrated the sustained release of OVA from the block copolymer gels when 
compared to a solution of protein alone diffusing through the PEG gel (Figure 3). 
Increasing the concentration of Pluronic in the vector gels decreased the rate of protein 
release, as hypothesized. The pentablock copolymers were designed to exhibit slower 
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dissolution compared to Pluronic gels[11]. The release kinetics demonstrated that the 
release of ovalbumin from 20 wt.% PDEAEM vector formulations was comparable to 
that from a Pluronic F127 formulation of higher concentration. These trends have been 
observed in previously published work[11,36]. The 25 and 30 wt.% Pluronic F127 and 
20 wt.% PDEAEM pentablock copolymer vector gels remained visibly present on the 
barrier gel even after day 7. 
5.4.3 Protein Stability Studies 
Due to the importance of preserving functionality of antigen through structure, the 
stability of ovalbumin protein in block copolymer formulations was studied. Evaluated 
block copolymer formulations include 20, 25 and 30 wt.% Pluronic F127 or 20 wt.% 
PDEAEM pentablock copolymers. The hydrogels containing ovalbumin were incubated 
in a 37°C shaker mimicking physiological temperature for 1 and 7 days. The protein was 
then extracted using dialysis. The primary structure of the protein was evaluated using 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 4). A 
dominant band at  40 kDa was present in all samples and consistent across both time 
points indicating no degradative changes in primary structure of the protein. In addition, 
the lack of any larger bands near the top of the gel indicate that no protein aggregation 
occurred upon release from the polymer matrix. 
The secondary structure of the protein was determined by circular dichroism 
(CD) between the wavelength range of 190–260 nm. It has been reported that OVA in 
solution exhibits a strong positive peak between 190 and 200 nm as well as a double-
negative peak with a 222 nm peak being slightly larger than the peak at 208 nm, 
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indicative of -helices and -helices+-sheet secondary structures[15,37]. After 7 days 
of incubation with block copolymers, there was no change in the CD spectra (Figure 5). 
The spectra of the OVA incubated with the block copolymers was consistent across 
samples, indicating stability across protein secondary structures.  
OVA consists of four independent domains and a helical reactive center loop that 
is flexible in solution[38]. The tertiary structure was assessed by a UV-vis 
spectrophotometer. OVA showed broad peaks of absorbance at approximately 240 nm 
and 280 nm without degradation between formulations (Figure 6). The spectra were 
consistent across both time points, showing preservation of the tertiary structure. 
An enzyme-linked immunosorbent assay (ELISA) was used to study the 
antigenicity of OVA before and after incubation with block copolymers. A monoclonal 
antibody against OVA was tested with protein incubated with the varying block 
copolymer formulations for 1 and 7 days. The activity of the protein was maintained and 
showed relatively minor differences after incubation with block copolymers of varying 
formulations. After 1 day of incubation, the protein incubated with the 20 wt.% Pluronic 
F127 retained 91% antigenicity as normalized to our OVA control while the other 
formulations retained an antigenicity of approximately 75%. After day 7, the formulations 
containing 20, 25 and 30 wt.% Pluronic F127 or 20 wt.% PDEAEM pentablock 
copolymer retained an antigenicity above 70% for all cases. The ELISA results with 
statistical significance can be found in Figure 7.  
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5.4.4 In Vivo Polymer Persistence 
In order to measure polymer persistence, a 20 wt.% Pluronic F127 hydrogel 
containing fluorescently labeled block copolymer was administered subcutaneously to a 
group of mice and images were taken with an in vivo live animal imager. Pluronic F127 
was selected over the pentablock copolymer for fluorescent labeling due to the known 
fluorescence quenching from the tertiary amine groups present in the outer blocks of the 
pentablock copolymer[39]. The solution of block copolymer containing the AF647 label 
was incubated on ice up to administration where the physiological temperature of the 
mice transitioned the polymer solution into a hydrogel. The mean fluorescence intensity 
(MFI) from the administered hydrogels, as shown in Figure 8, substantially diminished 
after several days, after which remained constant for up to several weeks. 
Representative images at the indicated time points post injection (Figure 9) show the 
localization and persistence of the hydrogels. This persistence of the hydrogel may 
contribute to the immune enhancing properties of the hydrogels since the depot effect is 
a known mechanism of adjuvanticity[40]. This hypothesis was then tested using the 
model antigen ovalbumin to gain a better understanding of the response to 
immunization with the block copolymers. Given that the pentablock copolymer 
hydrogels dissolve and release molecules at a slower rate than the Pluronic gels (see 
Figure 3 or ref [11]), the persistence in vivo of these pentablock copolymers is expected 
to be greater than the 50+ days seen with the Pluronic gels. 
5.4.5 In Vivo Immunization against OVA 
The humoral immune response of mice was evaluated by administering the 
polymer with OVA to several groups of mice and measuring the antibody response. In 
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addition to the groups included in the stability and release studies, 20, 25 and 30 wt.% 
Pluronic F127 or 20 wt.% PDEAEM pentablock copolymer, a new group was included 
containing a blend of 10 wt.% Pluronic F127 and 10 wt.% PDEAEM pentablock 
copolymer. It was hypothesized that this new formulation may benefit from the slow 
release properties of the pentablock copolymer and the high biocompatibility of Pluronic. 
The block copolymers significantly enhanced the immune response in mice in all cases 
(Figure 10). An increase in pentablock copolymer fraction in the formulation 
corresponded to an increase in antibody titers, showing that the addition of the cationic 
groups significantly enhanced the adjuvanticity of the polymers. 
At 2 weeks post immunization, the anti-OVA antibody titers of the mice 
administered block copolymers were six-fold greater than for the soluble OVA alone. 
The formulation containing 25 wt.% Pluronic hydrogel showed the highest and nearly 
tenfold greater values than for the protein alone. After 4 weeks, the groups containing 
pentablock copolymers accelerated above all other formulations. The antibody titers for 
the pentablock copolymer group at this time, were twentyfold greater than the soluble 
OVA control and at least three times higher than the groups containing only Pluronic. 
The titers were found to plateau at 4 weeks and differences between those and the 
values at the 6 weeks period were relatively minor. At this time, the differences between 
the soluble protein and pentablock copolymer groups remained the same; however the 
difference between Pluronic only and pentablock copolymer formulations decreased to 
a twofold difference.  
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The increase in the humoral immune response from the Pluronic and from the 
addition of the outer blocks was apparent from the in vivo immunization. The relatively 
higher antibody titers from the formulations containing pentablock copolymers may be 
due to the slower release kinetics that were observed in the barrier gel release studies. 
This would correlate with the known contribution of the depot effect to adjuvanticity. The 
increased humoral immune response from the pentablock copolymers may also be due 
to the cationic outer blocks as charge has been previously identified by other groups to 
impact vaccine efficacy[41,42].     
5.5 Discussion 
The potential of biocompatible polymers to entrap antigen in a polymer matrix 
and provide the sustained delivery of payload has led to several recent studies 
investigating novel vaccine adjuvants[1]. Here the importance of prolonged release in 
establishing long-lasting immunity must be balanced by stability of in the payload in the 
context of the polymeric microenvironment. Injectable block copolymer formulations that 
form thermoresponsive hydrogels at physiological temperatures have immense potential 
for antigen delivery systems. This includes pentablock copolymers based on Pluronic 
with tertiary amine groups in their outerblocks. Pentablock copolymers have previously 
demonstrated their ability to ensure sustained, efficacious gene delivery without 
sacrificing biocompatibility[19,20].  
In this work, we have demonstrated the ability of these block copolymers based 
on Pluronic to deliver a model protein antigen for potential use in subunit vaccines. It 
has been suggested that the sustained delivery of protein over time may increase the 
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immune response to a vaccine[43]. Release kinetics of ovalbumin encapsulated in gels 
with various concentrations of Pluronic were compared to release of ovalbumin from the 
pentablock copolymers. All formulations were able to prolong the release of ovalbumin 
protein through a barrier gel system designed to mimic in vivo conditions with the 
pentablock copolymers release profile demonstrating the slowest release of protein, 
over a period of several days.  
A major consideration for polymeric vaccine formulations is the issue of antigen 
stability during encapsulation, storage and release. For this reason, we also 
investigated the stability of ovalbumin protein after incubation with block copolymer 
hydrogels. The incubated protein retained its structure with very little differences in its 
primary, secondary and tertiary structures. Small differences arose in antigenicity after a 
week of incubation but the protein maintained a high relative antigenicity in all cases 
including incubation with the ionic pentablock copolymer.  
Next, we looked at the persistence of one specific block copolymer formulation to 
gain a better understanding of how an antigen-loaded hydrogel might perform in vivo. 
The polymer persisted strongly after several days and then dropped down to a level 
above background and continued to persist after several weeks. Given the trend seen in 
the in vitro OVA release kinetic experiment, we would expect a hydrogel constituted of 
the pentablock copolymer polymer to persist even longer than the triblock in vivo. We 
believe that the block copolymers ability to form long lasting hydrogels in vivo may help 
enhance the immunogenicity of the selected antigen.  
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Finally, we demonstrated the block copolymers’ ability to induce a humoral 
immune response by measuring antibody titers in mice immunized against OVA. 
Immunizations containing block copolymer led to at least fivefold higher antibody titers 
than those containing soluble OVA alone. The inclusion of the pentablock copolymer in 
the vaccine formulations further enhanced immunogenicity with titers as high as 
twentyfold compared to those containing soluble protein alone, indicating the expected 
increased immunogenicity due to the PDEAEM blocks. The kinetics of the response to 
immunization reflects the results observed in the in vitro antigen release experiments. 
The addition of 10% PDEAEM initially increased the antibody titer relative to the other 
groups; however by 4 weeks post-immunization, the animals immunized with the 20% 
PDEAEM formulation demonstrate the highest titers. This reflects the slower antigen 
release from the pentablock copolymer groups coupled with the increased antigenicity 
of the polymer as compared to Pluronic. This establishes the ability of a block 
copolymer platform to effectively adjuvant subunit vaccines.  
5.6 Conclusions 
In this work, we investigated and demonstrated the ability of a new cationic 
pentablock copolymer system, and the parent triblock Pluronic copolymers to form gels 
under physiological conditions, slowly release structurally intact and antigenically stable 
protein antigens in vitro, create an antigen depot through long-term injection-site 
persistence in vivo, and significantly enhance the in vivo immune response to these 
antigens. These results demonstrate the potential of these block copolymers to sustain 
the release of antigen with minimal effects on protein stability or antigenicity and the 
persistence of the hydrogel up to several weeks. The relatively high antibody titers of 
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mice immunized against OVA demonstrate the potential for block copolymers for use 
simultaneously as a sustained delivery device as well as a subunit vaccine adjuvant 
platform. 
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Figure 1: 1H NMR spectra of PDEAEM pentablock copolymer.   
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Figure 2: To carry out the release study, porous PEGDA barrier gels were set in wells 
containing permeable inserts. Vector formulations of block copolymer and OVA were 
injected onto an indent on top of the barrier gels. The barrier gels were then moved to a 
37 °C incubated shaker mimicking physiological conditions. This caused the vector 
solutions to transition into the gel phase. Release samples were taken by collecting and 
replacing the water at the bottom of the wells.  
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Figure 3: OVA release kinetics from block copolymer gels through PEG-DA barrier gels 
as measured by Micro BCA. Error bars indicate standard error of the mean.  
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Figure 4: SDS-PAGE results for (A) Day 1 and (B) Day 7 OVA samples in contact with 
various block copolymer gel formulations 
 
 
 
129 
 
 
Figure 5: Circular dichroism spectra for (A) Day 1 and (B) Day 7 OVA stability study 
samples in contact with various block copolymer formulations 
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Figure 6: UV-vis spectra for (A) Day 1 and (B) Day 7 OVA stability study samples in 
contact with various block copolymer formulations 
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Figure 7: ELISA for (A) Day 1 and (B) Day 7 OVA stability study samples in contact 
with various block copolymer formulations. Error bars indicate standard error of the 
mean. Statistical significance between groups was calculated with a one-way analysis 
of variance (ANOVA) followed by a Tukey’s post hoc test and a p-value  0.05.  
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Figure 8: The mean fluorescence intensity (A) and fraction of initial fluorescence (B) of 
mice administered fluorescently labeled 20 wt.% Pluronic F127 hydrogels. Error bars 
indicate standard error of the mean.  
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Figure 9: In vivo images at various time points of mice administered fluorescently 
labeled 20 wt.% Pluronic F127 hydrogels.  
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Figure 10: Humoral immune response measured at several time points for mice 
immunized with 100 µg of OVA in hydrogel formulations or a saline control. Error bars 
indicate standard error of the mean. Statistical significance was calculated with a one-
way analysis of variance (ANOVA) followed by a Tukey’s post hoc test and a p-value  
0.05. Letters indicate statistical differences within groups and asterisks indicate 
statistical significance between polymer groups and OVA at the corresponding time 
points.   
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6.1 Abstract 
 Injectable thermogelling biocompatible polymers have been recently investigated 
as novel adjuvants and delivery systems for next generation vaccines. As research into 
natural and synthetic biocompatible polymers progresses, the safety of these 
compounds is of critical concern. Cationic pentablock copolymers based on Pluronic 
F127, FDA approved for multiple applications, have been demonstrated to effectively 
create an antigen depot, minimally impact antigen stability, and enhance the immune 
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response to antigens. In this work, we investigate the safety and biocompatibility of the 
parent triblock Pluronic gels and our cationic pentablock copolymer gels with 
methacrylated PDEAEM outer blocks in a murine model. We demonstrate the induction 
of an increased level of lipids in the blood following the subcutaneous injection of a 
thermogelling Pluronic solution, with no further deleterious effects observed from the 
addition of the cationic outer blocks. This hyperlipidemia resolved by 30 days after the 
administration of the Pluronic. Histological analysis discovered no injection site reaction 
and no damage to the liver and kidneys was observed with any of the block copolymer 
formulations. The use of the polymer polyvinyl alcohol (PVA) in the hydrogel 
formulations, was found to allow gelation, while reducing the necessary amount of 
Pluronic. This abrogated the observed hyperlipidemia while preserving the antigenicity 
of the vaccine, as demonstrated through a robust humoral immune response.  
6.2 Introduction 
The design and implementation of novel vaccine adjuvants and vaccine delivery 
systems has the potential to offer a significant improvement over current vaccine 
technology. Biocompatible polymers have been recently investigated as novel adjuvants 
and delivery systems for next generation vaccines. As research into natural and 
synthetic polymers progresses, the safety of these compounds is of critical concern. 
There is a strong need to balance the immunostimulatory properties of vaccines with the 
desire to avoid injection site reactions such as pain, redness and swelling, which may 
lead to reduced patient compliance.  
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  These site reactions may be caused by adjuvants that are often necessary 
vaccine additives. These vaccine adjuvants have roles that include antigen delivery, 
immune modulation and enhancing an immune response1. The majority of vaccines that 
have been approved for human use contain potassium aluminum sulfate (alum), a 
squalene oil-in-water emulsion or monophosphoryl lipid A (MPLA). It is known that alum 
cannot adjuvant a cell-mediated immune response that is necessary to clear 
intracellular pathogens including influenza2,3. In addition, oil-in-water emulsions and 
MPLA have long been associated with inflammation4,5. 
Amphiphilic block copolymers consisting of polyoxypropylene and 
polyoxyethylene blocks, including the widely used, FDA approved surfactant Pluronic 
(see earlier comment) F127, have been evaluated as injectable drug and vaccine 
delivery systems with tunable release rates based on polymer concentration6. These 
polymers can deliver antigen in the form of an injectable delivery system that 
spontaneously gels at physiological temperature, creating a depot. Pentablock 
copolymers based on Pluronics, that have been synthesized in our laboratory with 
cationic outer blocks have been shown to electrostatically complex DNA and can be 
easily functionalized with pathogen associated molecular patterns to stimulate the 
immune response7. Based on this, pentablock copolymers may offer an improvement in 
current vaccine technologies. 
Pentablock copolymers are synthesized from Pluronic macroinitiators using atom 
transfer radical polymerization (ATRP). The addition of cationic blocks to the triblock 
copolymer impacts the overall toxicity of the polymer due to a combination of the 
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reactogenicity of the outer cationic bocks and the presence of residual copper catalyst 
from the ATRP reaction 8. To reduce the cytotoxic impact of the outer blocks, we have 
recently developed a new method of catalysis for ATRP to further reduce the toxicity of 
the pentablock copolymers. By replacing conventional soluble cuprous salts with easily 
removable cuprous oxide nanoparticles, we have shown that the final pentablock 
copolymers have a lower level of copper in the end product and a significantly reduced 
toxicity as determined by cellular cytotoxicity assays9. 
The unique thermoreversible properties of Pluronic F127 has led to a wide range 
of applications in drug delivery6. Although Pluronic F127 is widely used in FDA 
approved products, we and some others report a significant increase in the quantity of 
cholesterol and triglyceride present in the serum of mice administered Pluronic block 
copolymer hydrogels both with and without cationic outer blocks10.  For this reason, we 
propose a combination hydrogel based on pentablock copolymers containing cationic 
groups, triblock Pluronic PF127 and PVA which reduce the production of lipids and 
cholesterols induced by the injection of PF127 alone, while still retaining the ability to 
form a gel at physiological temperatures. Poly(vinyl alcohol) is a hydrophilic polymer 
with a high biocompatibility and an excellent safety profile, that is currently being 
investigated for a number of biomedical applications including wound healing11. Like our 
block copolymer system, the polymer PVA has gelation capabilities, often achieved 
through cross-linking via 	-irradiation or successive freeze/thaw cycles12. Crosslinking 
was not found to be necessary for gelation when used in combination with the block 
copolymers. This combination adjuvant system enhances the safety profile of the 
hydrogel vaccine platform, while maintaining its adjuvant capabilities. We demonstrate a 
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robust humoral immune response to immunization with the model antigen, ovalbumin, 
with immunized animals producing higher antibody titers as previously published work 
with PF127 and pentablock copolymer.  
6.3 Experimental Section 
6.3.1 Materials 
 Poly(vinyl alcohol) (PVA, MW = 9,000-10,000 g/mol, 80% hydrolyzed), N,N-
(diethyl amino)ethyl methacrylate (DEAEM), polyvinylpyrrolidone (Mn = 40000), Pluronic 
F127 (Mn = 12600, 70% PEO), ovalbumin protein (44 kDa), creatinine assay kit (45-
MAK080)  were purchased from Sigma-Aldrich (St. Louis, MO). All other materials 
including Multistix 10 SG reagent strips were purchased from Fisher Scientific 
(Pittsburgh, PA). The synthesis of N-propyl-pyridynyl methanimine (NPPM) from 1-
propylamine and 2-pyridinecarbaldehyde and cuprous oxide nanoparticles has been 
previously described9,13. 
6.3.2 Pentablock Copolymer Synthesis 
 Pentablock copolymer was synthesized from Pluronic F127 via atom transfer 
radical polymerization. The synthesis of the N-propyl-pyridynyl methanimine (NPPM) 
ligand, cuprous oxide nanoparticles and Pluronic macrointiator has been previously 
reported9,13. Pluronic macrointiator (10 g, 0.78 mmol) was added to a sonicated solution 
of cuprous oxide nanoparticles (.24 g, 1.68 mmol) in toluene. The reaction flask was 
degassed several times by vacuum-nitrogen before injecting the NPPM ligand (.5 mL, 
3.40 mmol) and DEAEM monomer (4 mL, 2.53 mmol). Several freeze-pump-thaw 
cycles with liquid nitrogen were used to further remove oxygen. The mixture was 
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reacted inside of a water bath at 70°C and 300 RPM. After 20 hours, the reacted 
product was passed through a column of basic alumina with a 1:1 
dichloromethane:toluene solution. The eluate was removed with a rotary evaporator and 
the polymer was precipitated in chilled n-heptane. The precipitant was collected using a 
Büchner funnel and left in a vacuum oven to dry overnight. The functionalization of the 
pentablock copolymers with mannose has been previously reported7. The average 
molar mass of the biocompatible polymers in all cases was kept below 17,000 g/mol to 
allow for renal clearance14. The functionalization of the pentablock copolymers with 
PAMPs via a high yielding azide-alkyne click reaction has been previously reported7. 
This provided polymers that were functionalized with mannose at both end blocks of the 
polymer. The block copolymers were incubated overnight on ice inside a solution of 
phosphate buffered saline (PBS) at concentrations exceeding 20 wt.%.This provided a 
hydrogel formulation that was a liquid at room temperature but gelled after 
administration due to higher physiological temperatures. 
6.3.3 Inclusion of PVA in Hydrogel Formulations 
 The PVA was added to the block copolymer system by first heating a 30 wt.% of 
the polymer in PBS at 80 °C for several hours to cause dissolution and the formation of 
a viscous solution. At high temperatures, the PVA was pipetted into a 20 wt% chilled 
block copolymer solution and briefly vortexed. The polymer solution of PVA and the 
block copolymers retained its ability to form a temperature dependent gel. 
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6.3.4 Mice 
 For these experiments, five to seven week old female albino C57BL/6 mice were 
purchased from Jackson Laboratories (Bar Harbor, ME). The Institutional Animal Care 
and Use Committee (IACUC) at Iowa State University approved all protocols involving 
animals. 
6.3.5 Administration of Hydrogels 
 To study the safety of the block copolymer hydrogels, a total of 16 mice per 
group were administered hydrogel formulations containing PF127 with or without non-
functionalized or mannose-functionalized PDEAEM penablock copolymers (referred to 
as m-PDEAEM or PDEAEM in short). (Maybe the abbreviation PDEAEM is confusing as 
it would refer to just a homopolymer of PDEAEM instead of a pentablock copolymer. 
Should we come up with a better abbreviation for the PDEAEM pentablock copolymers? 
) Additional groups included incomplete freund’s adjuvant (IFA) and saline. In a 
separate experiment, a total of 4 mice per group were immunized with 100 µg 
ovalbumin (OVA) with hydrogels containing PVA, PDEAEM and PDEAEM. Additional 
groups included alum and saline. All formulations were administered into the right side 
flank of the mice with a 26G 3/8 syringe. The hydrogel formulations were kept on ice 
until administration, at which time the mice’s physiological temperature caused the 
formation of a hydrogel on injection. Serum samples were collected via saphenous vein 
puncture at various time points throughout the experiment. 
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6.3.6 Serum and Urine Biomarker Analysis 
 Serum biomarkers of kidney and liver function were analyzed using Vitros 5.1 
Chemistry Analyzer. Multistix 10G Reagent Urine Testing Strips were used to measure 
glucose, bilirubin, ketones, specific gravity, blood, pH, protein, urobilinogen, nitrite and 
leukocytes. The strips were dipped and read visually in accordance to the provided 
instructions. Creatinine in the urine was measured with a separate  
6.3.7 Histopathological Evaluation 
 Kidney, liver and injection site tissue were fixed in formalin, embedded, sectioned 
and analyzed by a veterinarian pathologist in a blind study. Scores ranged from 0, 
indicating no change, to 5, the most severe being a diffuse change with tissue loss and 
architecture. The histopathological score for both liver and kidney ranged from 0 to 10 
and is a summation of inflammation and necrosis. The injection site histopathological 
score ranged from 0 to 15 and is a summation of inflammation, distribution of 
inflammatory cell infiltrate, fibrosis and tissue loss. 
6.3.8 Antibody Titers 
Antibody titers of immunized animals were measured with ELISA. OVA protein 
was incubated into each well of a high protein binding Costar® plate at a concentration 
of 1 µg/mL. After incubation overnight at 4 °C, the plates were washed three times with 
phosphate buffered saline containing 0.05% Tween 20 (PBST) and blocked with a 2.5% 
milk solution in PBST for 2 hours at room temperature. The plates were washed three 
times with PBST and mouse sera was added at a dilution of 1:200 to PBST and then 
diluted serially, 1 to 3 for a total of 12 dilutions. All samples were tested in duplicate. 
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The plates were incubated overnight at 4 °C. After three wash cycles with PBST, an 
alkaline phosphatase-conjugated anti-mouse IgG secondary antibody diluted 1:40,000 
was added to each well. The plates were incubated for 2 hours at room temperature. 
The plates were washed for three cycles with PBST. Alkaline phosphatase substrate 
was prepared in sodium carbonate buffer (pH 9.3) containing 1 mg/mL phosphatase 
substrate. A volume of 100 µL was added to each well. After 30 minutes of incubation, 
the optical density was measured at 405 nm using a plate reader. Antibody titer was 
defined as the dilution at which the optical density was greater than twice that of the 
average of the saline controls. 
6.3.9 Avidity 
 Avidity analysis was performed in the same manner as the antibody titer 
experiment. Ovalbumin was added into each well of a high protein binding Costar® 
plate at a concentration of 1 µg/mL followed by overnight incubation at 4 °C.  The plates 
were then washed three times with phosphate buffered saline containing 0.05% Tween 
20 (PBST) followed by the addition of 270 µL of a 2.5% milk solution in PBST for 2 
hours at room temperature. The plates were washed three times with PBST and 100 µL 
of mouse sera was added at a constant 1:200 dilution. After overnight incubation and 
three washed with PBST, a 5 M solution of sodium thiocyanate in a 0.1 M sodium 
phosphate buffer was added to the first well of each row followed by five two-fold serial 
dilutions across the row (i.e., for a final dilution of 1:32). Six control wells were used per 
sample and received sodium phosphate buffer alone. The solution was incubated for 15 
min before washing five times with PBST as described above. The addition of 
secondary antibody and the alkaline phosphatase substrate followed the steps 
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described above for antibody detection. To determine avidity index, an exponential fit of 
sodium thiocyanate serial dilutions was used to determine the concentration at which 
the optical density measures 50% of the average of the non-treated wells. All samples 
were tested in duplicate.  
6.3.10 Statistics 
 All error bars represent standard error of the mean with statistical significance 
designated as a p-value  0.05. Differences between groups were analyzed with one-
way analysis of variance (ANOVA) followed by Tukey’s post hoc test.  
6.4 Results 
6.4.1 Investigation of Block Copolymer Safety 
To investigate the biocompatibility of the pentablock copolymers, mice were 
subcutaneously treated with a varying ratio of non-functionalized and functionalized 
PDEAEM and PF127 block copolymers. These groups were compared to mice 
administered saline, IFA or PF127 alone. This comprehensive study included serum 
and urine analysis, a ProSense inflammation experiment, inflammatory cytokine 
analysis and histopathological analysis. Inflammation was also assessed with ProSense 
750, a fluorescent reagent that is activated by disease associated proteases, cleaved in 
the presence of a number of cathepsins, with no visible inflammation observed (Data 
not shown)15.  
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6.4.2 No Deleterious Histopathological Effects Observed due to Hydrogel 
Administration 
No inflammation was visualized in the polymer treated mice at Day 3 and Day 10. 
Histopathological analysis was utilized to look for signs of toxicity, inflammation or 
necrosis with little to no evidence of injection site reactions or damage to the kidney or 
liver at Day 3 or Day 30 of mice administered block copolymers. Furthermore, no 
significant differences were observed in kidney or liver weight (Figure 2).   
6.4.3 Urinalysis Indicated No Changes in Kidney Function  
The mouse urine collected at Day 1, Day 3, Day 14 and Day 28 was tested with a 
specialized creatinine analysis kit and Multistix 10 SG Reagent Strips. The amount of 
creatinine in the urine is indicative of kidney function. Creatinine is a metabolite of 
creatine and if the kidneys are damaged the quantity of creatinine in the urine may 
decrease16. There was little to no statistical difference in the quantity of creatinine in the 
urine of mice administered polymers when compared to those administered saline alone 
(Figure 3). The Multistix 10 SG Reagent Strips were dipped and then read visually. The 
strips are used to screen for a broad range of conditions including but not limited to 
urinary tract infections, diabetes and kidney disorders. No differences indicating an 
adverse reaction to the polymer were observed (Data not Shown).  
6.4.4 Block Copolymer Administration Induced Elevated Triglyceride and 
Cholesterol Levels at Early Time Points 
Serum collected at Days 3 and 30 were analyzed for biomarkers of kidney and 
liver function using Vitros 5.1 Chemistry Analyzer. We report that groups containing the 
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tri and pentablock copolymers exhibited elevated triglyceride and cholesterol levels 
indicative of hypertriglyceridemia and hypercholesterolemia at Day 3. This includes the 
treatment group of PF127 alone, which showed the highest increases, suggesting that 
the PF127 and not the cationic outer blocks are responsible for this observation. 
Although the mechanism for elevated levels of circulating triglycerides and cholesterol 
has not yet been elucidated it has been suggested that this may be in part due to the 
alteration of enzymes responsible for lipid metabolism17. Although the levels of 
triglycerides and cholesterol returned to normal levels at Day 30, this posed a 
considerable concern from the standpoint of establishing an efficacious and safe 
vaccine adjuvant. The correlation between high concentrations of Pluronic F127 and the 
onset of hypertriglyceridemia and hypercholesterolemia has also been previously 
reported by other groups17,18. Since the Pluronic F127 is the basis of the hydrogel it 
cannot be completely eliminated however there is an urgent need to reduce its 
concentration in the final formulation.   
6.4.5 Reducing PF127 Weight Through the Addition of PVA in Hydrogel 
Formulations Reduces Serum Triglyceride and Cholesterol Levels 
We have previously reported that the block copolymer hydrogel establishes a 
depot at the injection site while sustaining the release of antigen. However, the high 
quantity of PF127 needed to form a hydrogel are also responsible for elevated levels of 
triglycerides and cholesterol. Therefore, there was an urgent need to preserve the 
integrity of the depot while reducing the quantity of PF127. A combination of PF127 and 
poly(vinyl alcohol) (PVA) has been explored for the intent of establishing a 
biocompatible temperature responsive delivery device19. In addition, the safety of 
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subcutaneously administered PVA has already been studied. Repeated administration 
of high quantities of low molecular weight PVA has been shown to produce no 
abnormalities or systemic effects20. For this reason, we developed a formulation 
containing PVA to evaluate the addition of PVA to our block copolymer platform.  
The polymer solution of PVA and Pluronic and pentablock copolymers retained 
its ability to form a temperature dependent gel. The resulting formulation containing 
PDEAEM, PF127 and PVA was subcutaneously administered to the left flank of mice. In 
addition to two groups containing the PDEAEM:PF127:PVA formulation at different 
ratios, an alum and protein alone group were added as controls. The model antigen 
ovalbumin, 100 µg, was added to the hydrogel and control groups in order to measure 
the immune response to this new polymer formulation. The serum biomarker analysis at 
Day 3 showed that the PVA inclusive polymer formulations had triglyceride and 
cholesterol values much closer to normal ranges (Data not Shown), likely due to the 
reduced levels of PF127 necessary to form the hydrogels.  
6.4.6 The Addition of PVA to the Hydrogel Formulations Led to Increased Anti-
OVA Antibody Levels 
The antibody titers for the PDEAEM:PF127:PVA polymer formulations were 
several folds higher than those for alum and protein alone. The increasing concentration 
of PDEAEM in the formulation was proportional to an increase an antibody titers. The 
difference between these two groups was statistically significant for up to 6 weeks. The 
avidity of these titers were equivalent to the other formulations (Data not Shown). The 
addition of PVA to the block copolymer reduced the risk of hypertriglyceridemia and 
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hypercholesterolemia while outperforming in the magnitude of the immune response 
from previous formulations. 
6.5 Discussion 
Our research group has previously synthesized a family of pentablock 
copolymers based on the amphiphilic Pluronic F127 triblock copolymer. This family of 
pentablock copolymers differ in their cationic outerblocks and therefore differ in their pH-
dependent micellization behavior. These polymers have been synthesized with reduced 
toxicity by catalyzing the atom transfer radical polymerization reaction with easily 
removable cuprous oxide nanoparticles. Block copolymers synthesized via this novel 
catalyst are essentially copper free leading to reduced toxicity than those synthesized 
with traditional cupric salts9. After an initial comparison between the pentablock 
copolymer families, the PDEAEM pentablock copolymer was selected as an optimal 
candidate as a vaccine delivery vector7. This polymer was successfully functionalized 
with pathogen associated molecular patterns (PAMPs) for the intent of activating pattern 
recognition receptors (PRRs) on antigen presenting cells (APCs)7. The activation of 
PRRs on APCs by carbohydrate decorated polymers has been demonstrated  to 
upregulate the expression of MHC II, costimulatory molecules and c-type lectin 
receptors by dendritic cells21. In addition to functionalizing our polymers with PAMPs, 
our research group has demonstrated the preservation of primary, secondary and 
tertiary structures as well as antigenicity of released protein. This complements the 
ability of the platform to form long lasting depots that can sustain the release of antigen 
over time. As research into these promising biocompatible polymers progresses, a 
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thorough safety study and an evaluation of the immune response is necessary to 
ensure the in vivo safety of these novel biomaterials.   
Our results show that there were little to no evidence of injection site reactions or 
damage to the kidney or liver. However, we did observe high levels of triglycerides and 
cholesterol in treatment groups administered PF127. To preserve the ability of the block 
copolymers to sustain the release of antigen, we explored an alternative method of 
forming an antigenic depot with a reduced quantity of the Pluronic block copolymer. The 
elevation of circulating triglycerides and cholesterol is well known to be dependent on 
the amount of Pluronic F12717,18. The addition of PVA to the formulation allowed the 
formation of a hydrogel with lower concentrations of PF127 thereby reducing the risk of 
hypertriglyceridemia and hypercholesterolemia. The PVA-inclusive hydrogel 
formulations were also found to produce high magnitude immune responses.    
6.6 Conclusions 
We have previously synthesized a family of biocompatible pentablock 
copolymers and functionalized them with PAMPs for use as vaccine adjuvants. After an 
initial comparison, we have selected the optimal PDEAEM pentablock copolymer and 
demonstrated its ability to preserve protein stability and antigenicity. As research into 
these polymers continues, the safety of these compounds is of critical concern. In this 
work, we investigate the safety and biocompatibility of the Pluronic and our cationic 
pentablock copolymer in a murine model. Histological analysis discovered no injection 
site reaction or damage to the liver and kidneys was observed with any of the block 
copolymer formulations. We observed the induction of an increased level of lipids in the 
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blood following the subcutaneous injection of a Pluronic hydrogel. This hyperlipidemia 
resolved by 30 days after the administration of the PF127. The use of the polymer 
polyvinyl alcohol (PVA) in the hydrogel formulations, to reduce the necessary amount of 
Pluronic abrogated the observed hyperlipidemia, while preserving the antigenicity of the 
vaccine, as demonstrated through a robust humoral immune response. 
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Figure 1: Composite histopathological scores of kidney, injection site and liver at day 3 
and day 30 for PDEAEM:PF127 and control mice. 
 
Figure 2: (A) Kidney and (2) liver organ weight at day 3 for PDEAEM:PF127 and control 
mice. 
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Figure 3. Total creatinine present in the urine for PDEAEM:PF127 and control mice at 
day 1, day 3, day 14 and day 28. 
 
Figure 4: Antibody titers of PDEAEM:PF127 and control mice. 
155 
 
 
Figure 5: Antibody avidity of PDEAEM:PF127 and control mice. 
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CHAPTER 7: BLOCK COPOLYMER VACCINE CHALLENGE 
STUDIES WITH LOW PATHOGENIC H5N1 VIRUS 
 
A paper currently in preparation 
 
7.1 Introduction 
Highly pathogenic avian influenza A (HPAI) H5N1 represents a significant global 
threat, with documented cases in at least 15 countries, with the highest numbers in 
Indonesia, Egypt and Vietnam. Up to 600 human cases of HPAI H5N1 have been 
reported with up to 60% mortality1. Typically transmitted to humans through contact with 
infected poultry, this virus cannot effectively transmit between humans, though limited 
instances of human-to-human transmission have been reported1. This is a concern 
however as the segmented influenza genome has a high reassortment rate and may 
gain the ability to transmit between human hosts2.  
Currently there a few vaccines against HPAI H5N1, including vaccines 
manufactured by GlaxoSmithKline (GSK) Biologicals3. These vaccines have been 
demonstrated effective against currently circulating strains of influenza. However, in the 
event of a pandemic strain, a new vaccine may need to be rapidly developed as most 
killed or attenuated vaccines fail to provide cross-protection against strains4. Due to 
these limitations of killed and attenuated influenza vaccines, much of the current 
research on next-generation vaccine technologies has focused on viral subunits such as 
influenza surface proteins as protective antigens. Two major influenza surface proteins 
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are hemagglutinin (HA) and neuraminidase (NA), responsible for attachment to interior 
host cell surfaces by binding to sialic acid groups, and cleavage of these sialic acid 
groups for viral release from the host cell, respectively5,6.  
The surface protein, hemagglutinin is highly variable, with at least 18 subtypes 
currently identified7. Due to its relatively high antigenicity and critical role in influenza 
infection, HA has been identified as a protective antigen for influenza vaccine research8. 
Hemagglutinin exists in its native form as a trimer, with three identical protein monomers 
forming an -helical coil capped by three sialic acid binding sites9. Most influenza 
vaccine research using HA proteins as protective antigens has focused on monomeric 
HA protein due to the relative difficulty of expression and purification of the HA trimer. 
Recently, the Carpenter laboratory reported the successful expression of H5 trimer (H5-
T) using insect cells10. This protein was determined to be stable and antigenic, eliciting 
neutralizing antibody titers when administered to mice10.  
Polyanhydride nanoparticles have previously been demonstrated to be highly 
effective as vaccine delivery vectors, in the form or nanoparticles, and as adjuvants for 
poorly immunogenic protein subunits11. The chemistry of this class of biodegradable 
polymers can be tailored to release antigen quickly upon delivery, or provide a 
sustained release of antigen over a period of up to several months12. This continual 
exposure to antigen may reduce the amount of antigen needed for a protective immune 
response, dose sparing, or reduce the number of immunizations required, with 
implications for patient compliance13. The hydrophobic chemistry and surface 
degradation mechanism of these polymers have been shown to protect encapsulated 
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antigen from degradation from prolonged exposure to water and from the acidic 
microenvironment created by other biodegradable polymers such as polyesters12. 
Previously the Narasimhan lab has reported a protective immune response of mice 
immunized with H5-T encapsulated into polyanhydride nanoparticles in a three-dose 
regimen.   
Due to their small size, 200-400 nm, polyanhydride nanoparticles have been 
shown to disseminate quickly after administration14. In this work, we investigate the 
effects of formulating polyanhydride nanoparticles into hydrogels to create an antigenic 
depot of the particles and soluble H5-T, followed by the sustained release of H5-T from 
the polyanhydride particles. The hydrogels used consist of three polymers, Pluronic 
F127 (PF127), a pentablock copolymer based on PF127 with cationic 
polydiethylaminoethyl methacrylate outer blocks (PDEAEM), and polyvinyl alcohol 
(PVA). Hydrogels of PF127 have previously been demonstrated to create a depot at the 
injection site, due to the temperature dependent gelation properties of the PF127, with 
rapid decay for 3-4 days after administration followed by minimal persistence for up to 1 
months. Additionally, the Mallapragada lab has reported incidence of hyderlipidemia 
and elevated levels of cholesterol upon administration of concentrations of PF127 
required to form a gel. The concentration of PF127 required can be significantly reduced 
by lowering the amount of PF127, but with the addition of PVA to the formulation to still 
ensure gel formation, thereby reducing the elevated lipid and cholesterol levels 
observed15.  
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To investigate the efficacy of the optimized pentablock copolymer system, mice 
were immunized with hydrogel and polyanhydride nanoparticle adjuvant formulations 
containing H5 trimer. Treatment groups include: saline, H5 trimer alone, optimized 
hydrogel formulation, secondary adjuvant, optimized hydrogel formulation + secondary 
adjuvant and naïve mice. The mice were challenged with a low pathogenic influenza A 
H5N1 virus obtained from the Centers for Disease Control. Evaluation of neutralizing 
antibody titers in the serum of mice collected at days 35 and 70 demonstrate high titers 
in animals immunized with the H5-T in the hydrogel, and in polyanhydride nanoparticles 
co-formulated with the hydrogel. Similar results were observed in measured weight loss 
after challenge with the low pathogenic H5N1. Weight loss was mitigated in all of the 
vaccine groups compared to the control animals with the polyanhydride nanoparticle 
and hydrogel groups performing the best. Additional experiments include viral load, and 
the evaluation of cytokines from bronchiole alveolar lavage fluid collected three days 
after challenge. 
7.2 Methods 
7.2.1 Production and Purification of H5-T Protein 
The H5 trimer protein is from A/WhooperSwan/Mongolia/244/05, a clade 2.2 
virus. The synthesis of the protein by Dr. Carpenter’s Lab has been previously 
described10. 
7.2.2 Synthesis of PDEAEM Pentablock Copolymer 
The synthesis of PDEAEM pentablock copolymer with cuprous oxide 
nanoparticles from pluronic macrointiator has been previously described16. Briefly, 
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pluronic macrointiator (10 g, 0.78 mmol) was added to a solution of cuprous oxide 
nanoparticles (.24 g, 1.68 mmol) in 50 mL of toluene inside of a round-bottom flask. The 
reaction flask was degassed by vacuum-argon three times to remove air after fitting with 
a rubber stopper and cable tie. The NPPM ligand (.5 mL, 3.40 mmol) and DEAEM 
monomer (4 mL, 2.53 mmol) were carefully added into the reaction flask. Several 
freeze-pump-thaw cycles with liquid nitrogen were used to further remove oxygen. The 
reaction was carried out inside of a water bath at 70°C and 300 RPM for 20 hours. The 
reacted product was passed through a column of basic alumina with a 1:1 
dichloromethane:toluene solution/ The eluate from the column was evaporated with a 
rotary evaporator and the polymer was precipitated in chilled n-heptane. The precipitant 
was collected using a Büchner funnel and dried inside a vacuum oven. The molecular 
weight was determined using 1H NMR (Varian VXR300). 
7.2.3 Synthesis of 20:80 CPTEG:CPH Polyanhydride Polymer 
Monomers of 1,6-bis(p-carboxyphenoxy) hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) were synthesized as previously 
described14. The molar ratio of the polymer and molecular weight were determined 
using 1H NMR (Varian VXR300). 
7.2.4 Synthesis of H5T-loaded Nanoparticles 
 Polyanhydride nanoparticles loaded with 1% (w/w) H5-T were synthesized using 
a water/oil/oil encapsulation process. Briefly, H5-T protein provided by the Carpenter 
laboratory was concentrated using Vivaspin centrifugal concentrators. The concentrated 
protein solution was then added to the 20:80 CPTEG:CPH polymer dissolved at a 
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concentration of 20 mg per mL in methylene chloride. The resulting solution was then 
sonicated for 30 seconds at 40 Hz before precipitation in chilled pentane at a solvent to 
antisolvent ratio of 1 to 250. 
7.2.5 Preparation of Vaccine Formulations 
To create the PDEAEM:PVA:PF127 hydrogel formulation, a 30 wt.% poly(vinyl 
alcohol) (PVA) solution in PBS was heated to -80 °C for several hours to cause 
dissolution and the formation of a viscous gel. Immediately after heating, the PVA gel 
was pipetted into a 20 wt% chilled block copolymer solution and briefly vortexed. This 
polymer solution of PVA and block copolymers retained its ability to form a temperature 
dependent gel. Before subcutaneous administration, the PDEAEM:PVA:PF127 hydrogel 
was stored inside a cooler filled with ice. The formulation was vortexed before loading 
into a 26G 3/8 syringe that was allowed to reach room temperature before injection. 
7.2.6 Mice 
Studies were performed with 7 to 8 week old BALB/C mice.   
7.2.7 Viral Challenge 
The mice were challenged with a low pathogenic influenza A/H5N1 VNH5N1-
PR8CDC-RG obtained from Centers for Disease Control and Prevention (Atlanta, GA). 
The virus is a PR-8-based reassortant virus that contains the HA and NA genes of the 
H5N1 A/Vietnam/1203/04 clade 1 virus.  
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7.2.8 Statistics 
All error bars represent standard error of the mean. Differences between groups 
were analyzed with one-way analysis of variance (ANOVA) followed by Tukey’s post 
hoc test. 
7.3 Results & Discussion  
The Narasimhan lab has previously reported a protective immune response of 
mice immunized with H5-T encapsulated into polyanhydride nanoparticles in a three-
dose regimen.  However, these polyanhydride nanoparticles have been shown to 
disseminate quickly after delivery due to their small size, 200-400 nm 14. In this work, we 
investigate the effects of formulating polyanhydride nanoparticles into hydrogels to 
create an antigenic depot of the particles and soluble H5-T, followed by the previously 
demonstrated sustained release from the biodegradable particles.  We also investigate 
the efficacy of the pentablock copolymer hydrogel loaded with the H5 trimer alone in 
eliciting a protective immune response. Treatment groups included: saline, H5 trimer 
alone, optimized hydrogel formulation, secondary adjuvant, optimized hydrogel 
formulation + secondary adjuvant and naïve mice.  This work was performed using a 
prime-boost regimen, with implications for dose sparing and patient compliance, as 
compared to previous work with the polyanhydride nanoparticles.  
Schematic 1 outlines the experimental design for this study. Animals were 
immunized on days 0 and 21 followed by serum collection at days 35 and 70.  Mice 
were then challenged with a low pathogenic influenza A H5N1 virus obtained from 
Centers for Disease Control. Weight loss was monitored for 14 days after infection. 
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Additionally bronchiole alveolar lavage fluid was collected at three days after challenge 
to analyze viral load and the cytokine profile elicited from challenge 
7.3.1 Optimized Hydrogel Formulation with and without Secondary Adjuvant 
Elicits Increased Neutralizing Antibody Titers 
Evaluation of neutralizing antibody titers in the serum of mice collected at days 
35 and 70 demonstrate high titers in animals immunized with the H5-T in the hydrogel 
and in polyanhydride nanoparticles co-formulated with the hydrogel. Adjuvant 
formulations contained high magnitudes of a quality antibody response at Day 35 
(Figure 1). The optimized hydrogel formulation groups had the highest neutralizing 
antibody titers. These hydrogel groups also had a lower variability than polyanhydride 
nanoparticles alone. The decrease in variability from inclusion of the nanoparticles into 
the hydrogel may be due to a reduction in nanoparticle aggregation at the time of 
injection. These high neutralizing antibody titers persisted up to the date of infection at 
Day 70 (Figure 2). A group containing a combination of the hydrogel and nanoparticles 
elicited the highest titers at both time points.  
All groups showed signs of recovery after challenge with the low pathogenic 
H5N1 virus (Figure 3). The block copolymer hydrogel mitigated the onset of clinical 
signs in mice infected with influenza. Mice immunized with nanoparticles suspended in 
hydrogel had little to no difference in weight loss to naïve mice. These results show the 
benefit of a cocktail of multiple systems with different mechanisms of adjuvanticity for 
maximum efficacy. Additional analysis of antibody titers, cytokines and viral load is 
ongoing. 
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7.4 Conclusions 
We report the successful development of an influenza vaccine formulation of an 
optimized pentablock copolymer gel. In addition, this formulation also enhanced the 
immune response to polyanhydride nanoparticles delivered in the hydrogel. Delivery 
within the polymeric gel reduced the number of doses required for protection from a 
three dose vaccine regimen to a prime-boost regimen, having implications in patient 
compliance.  Additionally, the amount of antigen required was reduced from 30 µg 
reported in previous work with H5-T nanovaccines to 20 µg.  Dose sparing of antigen 
may reduce overall cost and result in expedited vaccine production.  We also observed 
a reduction in variability of the immune response, as measured by neutralizing antibody 
titer, for antigen delivered using the pentablock copolymer gels as a vector. 
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7.6 List of Figures & Tables 
 
Figure 1: Neutralizing antibody titers of treated mice at Day 35. Treatment groups 
include the optimized hydrogel formulation and a secondary formulation of 
polyanhydride nanoparticles.  
 
Figure 2: Neutralizing antibody titers of treated mice at Day 70. Treatment groups 
include the optimized hydrogel formulation and a secondary formulation of 
polyanhydride nanoparticles. 
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Figure 3: Weight change over time after infection with a low pathogenic influenza A 
H5N1 virus. Treatment groups include the optimized hydrogel formulation and a 
secondary formulation of polyanhydride nanoparticles. 
 
 
Schematic 1. Outline of Challenge Experiment 
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CHAPTER 8: CONCLUSIONS AND FUTURE WORK 
In this thesis we have investigated pentablock copolymers based on pluronic as 
a potential vaccine delivery platform. First, we demonstrated an improved method for 
polymer synthesis using easily removable cuprous oxide nanoparticles in place of 
soluble copper to catalyze the reaction resulting in lower cytotoxicity. This result has 
important implications for the transition to an in vivo vaccine formulation. Lower 
amounts of residual copper will lead to a safer vaccine with reduced adverse side 
effects.  
We next took advantage of the bromine–terminated end groups of the block 
copolymers to functionalize with mannose through an azide-alkyne click reaction. The 
addition of mannose has the potential to increase the efficacy of a vaccine based on the 
pentablock copolymers through the activation of immune cells by pattern recognition 
receptors. A comparison of different mannose functionalized pentablock polymers was 
performed to determine the optimal chemistry for a vaccine formulation and to 
determine the effects of the addition of mannose on the chemical properties of the 
polymers. PDEAEM-based pentablock copolymers were selected as the optimal 
polymer chemistry based on DNA condensation and cytotoxicity studies. It was also 
found that the addition of mannose to the polymers had no effect on the ability of the 
polymer to condense with DNA.  
Next, we evaluated the ability of these pentablock copolymers to deliver 
structurally intact and antigenically stable protein. We also evaluated the sustained 
release of model protein antigen in vitro and the ability of the block copolymer system to 
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form in vivo depots. These results demonstrate the potential of these block copolymers 
hydrogels to persist for several weeks and sustain the release of antigen with minimal 
effects on protein stability and antigenicity; and their ability to be used simultaneously as 
a sustained delivery device as well as a subunit vaccine adjuvant platform by enhancing 
antibody titers. 
We followed this work with a comprehensive safety study of the block copolymer 
system. We investigated the biocompatibility of our platform with a ProSense 750 
inflammation study, histopathological analysis as well as serum and urine biomarker 
analysis. In response to discovering dose-dependent hyperlipidemia in mice 
administered Pluronic F127, we made additional modifications to the hydrogel 
formulation to decrease the amount of Pluronic. We then demonstrated the safety of this 
optimized formulation as well as its capacity to instigate enhanced immune responses. 
 Finally, a low pathogenic influenza H5N1 challenge study in collaboration with 
the University of Nebraska Medical Center in Omaha, Nebraska was carried out to 
evaluate the efficacy of the optimized formulation. Hydrogel formulations contained high 
magnitudes of a quality antibody response after administration. After infection, the block 
copolymer hydrogels mitigated the onset of clinical signs in mice infected with influenza 
compared to controls. This combined work establishes the pentablock copolymer 
system as a highly efficacious vaccine platform.   
Ongoing and future work includes the application of the optimized hydrogel 
formulation to both an H1 and additional H5 challenge study at the University of Iowa 
and St. Jude respectively. This includes a continued collaboration with the Dr. 
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Narasimhan lab to delivery polyanhydride nanoparticles entrapped in a block copolymer 
hydrogel formulation to take advantage of the differing release kinetics from both 
platforms. In addition, future studies can focus on the combined DNA and protein 
delivery using these pentablock vaccine carriers as adjuvants.  
